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ABSTRACT 
Oligodendrocytes produce an immense quantity of polarized membrane, myelin, that 
ensheaths axons in the central nervous system. Myelin facilitates efficient communication and 
also provides metabolic and trophic support to axons. My studies show that the AKT/mTOR 
signaling pathway regulates oligodendrocyte differentiation and myelination through multiple 
mechanisms. Oligodendrocyte precursor cells (OPCs) undergo extensive cellular remodeling as 
they extend and retract filopodial-like processes while they proliferate and migrate. OPCs then 
differentiate and begin producing myelin. These processes require tight molecular and 
cytoskeletal control. Through in vivo manipulations, my studies demonstrate that mTOR 
promotes oligodendrocyte morphological differentiation, promotes myelin gene expression by 
suppressing BMP, and the downstream target S6 kinase1 determines the number of myelin 
internodes produced per cell. These studies also show that AKT promotes oligodendrocyte 
differentiation and myelination through the cytoskeletal regulator p21-activated kinase1 
(PAK1),  which regulates oligodendrocyte morphological differentiation and myelin production 
in the central nervous system. A combination of in vitro and in vivo models demonstrate that 
PAK1 is expressed throughout the oligodendrocyte lineage with highest expression in 
differentiated oligodendrocytes. Further, inhibiting PAK1 early in oligodendrocyte development 
decreases oligodendrocyte morphological complexity and alters F-actin spreading at the tips of 
oligodendrocyte progenitor cell processes. Constitutively activating AKT in oligodendrocytes, 
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which leads to excessive myelin wrapping, leads to an increase in PAK1 expression, suggesting 
an impact of PAK1 during active myelin wrapping. Conversely, inhibiting PAK1 during active 
myelination leads to a decrease in internode length. These data support a model in which PAK1 
is a positive regulator of CNS myelination and that AKT promotes oligodendrocyte 
differentiation and myelination through multiple mechanisms. 
The form and content of this abstract are approved. I recommend its publication. 
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 One of the most basic, yet most complex, tasks in biology is membrane process 
extension within a diverse extracellular matrix. This intricate task is involved in targeted cellular 
migration and in polarized membrane extension during cellular differentiation. It involves 
sensing the local environment, circumventing and/or interacting with extracellular proteins and 
other cells, ultimately reaching a final destination, and differentiating into a mature cell. After 
reaching their final destination, cells continue to extend processes throughout their 
environment, gathering information and obtaining their mature morphology. For example, in 
the central nervous system, oligodendrocyte precursor cells (OPCs) must proliferate, migrate 
and differentiate through multiple developmental stages to become myelinating 
oligodendrocytes that ensheath axons, increasing the speed of action potential propagation as 
well as providing metabolic and tropic support to neurons (1). Although we know a lot about 
the morphological changes involved in oligodendrocyte differentiation and myelination, less is 
known about the mechanisms that control these processes (Figure 1.1). 
Investigating oligodendrocyte biology is important as increases in oligodendrocyte density and 
myelination are associated with learning complex motor tasks (2), whereas disruption of myelin 
causes neuropathy and cognitive decline in diseases such as multiple sclerosis (MS) (3). 
                                                     
1 Portions of this chapter were previously published in Brown, T. L., & Macklin, W. B. (2019). 
The Actin Cytoskeleton in Myelinating Cells. Neurochemical Research, 6(6), 22741–10 and are 










Figure 1.1 Oligodendrocyte development. Neural precursor cells are specified to become 
oligodendrocyte precursor cells (OPCs). OPCs migrate while extending and retracting filopodial-
like processes. Oligodendrocytes reach their final destination where they differentiate into 
premyelinating oligodendrocytes and then myelinating oligodendrocytes. One oligodendrocyte 




Myelin in disease 
Multiple lines of evidence demonstrate that myelin provides trophic and metabolic 
support to axons, indicating that myelin is required for more than conduction velocity. Mouse 
models with mutations to myelin genes, including proteolipid protein1 (Plp1), 2’3’-cyclic 
nucleotide-3’phosphodiesterase (CNPase), and myelin oligodendrocyte glycoprotein (Mog), 
show relatively normal myelin structure but eventually lead to axonal pathology and behavioral 
issues (4-6). These data highlight the multiple roles myelin plays in promoting neural health. 
Many diseases also demonstrate myelin disruption, either in demyelinating diseases that affect 
myelin after the development of myelin, or in dysmyelinating diseases that affect myelin during 
the development of myelin itself.  
 Multiple sclerosis. One of the most well-known demyelinating diseases is the immune-
mediated CNS disease, multiple sclerosis (MS). MS is a major cause of nontraumatic 
neurological disability in North America (7,8). MS is characterized by plaques or focal areas of 
demyelination that span both the gray matter, areas with fewer myelinated axons, and white 
matter, areas containing a high density of myelinated fibers (3,9). MS progresses in three main 
patterns. Relapsing remitting MS (RRMS) is characterized by phases of increased symptoms and 
then subsequent improvement. Eventually most MS patients transition to secondary 
progressive MS (SPMS) with continuous deterioration or neurological symptoms without 
improvement. A subset of patients show primary progressive MS (PPMS) with the continuous 
disease progression from disease onset. MS patients display myriad symptoms with lesion 
location influencing pathology, ranging from motor to cognitive deficits, to numbness and 
fatigue (10,11). Traditionally, MS was thought of as a primarily white matter disease. Recent 
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data suggest that demyelination in gray matter significantly contributes to disease pathology as 
cognitive dysfunction is highly correlated with cortical lesion load but is only mildly correlated 
with white matter lesion load. This also suggests that gray matter myelination is critical for 
cognitive function (12).  
 Initially MS patients are able to remyelinate demyelinated areas but eventually 
remyelination fails, leading to increased disease pathology, brain atrophy, and cognitive decline 
(13-15). Evidence indicates that remyelination prevents axonal loss in both rodent models and 
MS patients, suggesting remyelination is crucial to maintain axonal integrity (16). While 
oligodendrocytes are present in early stages of MS, they decrease with disease progression 
(17). Most MS therapies focus on modulating the immune response in MS with few therapies 
targeting remyelination (18). In areas of active remyelination, there are proliferating OPCs as 
well as mature oligodendrocytes (19-21). The number of OPCs and mature oligodendrocytes in 
lesions decreases over time (22,23). In chronic MS lesions, there is a decrease in mature 
oligodendrocytes, suggesting that a failure of OPCs to differentiate in demyelinated plaques 
may contribute to ineffective remyelination (24). This also presents increasing oligodendrocyte 
differentiation as a potential therapeutic target.  
Most therapeutic targets focus on immune-modulation and focus on reducing relapses 
and disease progression (9). No therapies exist that improve disease through repair. 
Investigating oligodendrocyte differentiation and myelination is a promising area of research 
that may address this issue. In a rodent model of hypomyelination, shiverer mice lack a 
functional mbp protein. This leads to hypomyelination, trembling, and premature death 
(25,26). Transplantation of human glial progenitor cells into immune-deficient shiverer mice at 
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birth, increased myelination in the CNS and extended survival of a subset of mice (27). Multiple 
other studies have transplanted induced pluripotent stem cells (iPSCs) or iOPCs into rodent 
models of MS and demyelination with encouraging results, suggesting that transplantation of 
various stem or precursor cells may provide a viable therapeutic option for demyelinating 
disease(28). Additionally, investigators recently showed that iPSCs derived from PPMS patient 
fibroblasts transplanted into immune-deficient shiverer mice produced functional myelin (29).  
To date, no clinical trials use iPSCs or iOPCs to treat MS, despite that fact that rodent 
and in vitro data indicate that stem cell transplantation may provide a viable treatment option 
for MS patients. It also emphasizes the need to further understand the signals that control 
oligodendrocyte development, from the signals that specify NSCs to OPCs, to the signals that 
regulate OPC differentiation and myelination. As we increase our understanding of 
oligodendrocyte biology in normal development, we will be able to better understand the 
underlying mechanisms in disease states such as MS. 
Oligodendrocyte dynamics in MS. Recent data show that most MS patients do not 
generate new mature oligodendrocytes, suggesting that pre-existing oligodendrocytes are 
responsible for remyelination in MS (30). Additionally, single-nucleus RNA sequencing from 
demyelinated areas, normal appearing white matter (NAWM) in MS patients, or unaffected 
control patients show subpopulations of oligodendrocyte populations. They also show MS 
plaques with reduced levels of certain oligodendrocyte populations and that NAWM differs 
significantly from control WM (31). These data suggest that demyelinated plaques lead to 
widespread alterations to surrounding areas of the CNS, more than simply the active zone of 
demyelination.  
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Demyelinated plaques from MS patients show deficits in specific subpopulations of 
oligodendrocytes, predicted to be subsets of differentiated, mature oligodendrocytes (31). This 
suggests that OPCs fail to differentiate into mature, myelinating oligodendrocytes in plaques. 
The identification of subsets of mature oligodendrocytes in patient samples is an intriguing 
finding consistent with rodent data that identified populations of oligodendrocytes with greater 
heterogeneity than previously thought (32,33). Although these populations have recently been 
identified by specific transcriptional profiles, the function of each population remains unclear. 
Do individual oligodendrocyte populations have different myelination capacity? Are individual 
populations responsible for remyelination in disease states? It will also be important to 
determine the signaling that regulates the specification of each population. 
 Oligodendrocyte and myelin changes in neurological disorders and diseases. For many 
years, MS has been the predominate disease associated with changes to white matter due to 
obvious demyelination. However, there has been a surge of new data showing myriad 
neurological diseases with alterations to myelin. Some of these diseases include Alzheimer’s 
disease (AD) (34) and schizophrenia (SZ) (35,36). In both AD and SZ pathology, there are 
reduced numbers of oligodendrocytes along with reduced myelin integrity and altered myelin 
patterns. Similarly, patients with autism spectrum disorder (ASD) also show alterations to white 
matter. ASD patients show decreased white matter integrity in the corpus callosum (for review 
see (37)), while a mouse model of ASD shows decreased oligodendrocyte lineage cells and 
hypomyelination (38,39). These data indicate that oligodendrocyte development and 
myelination play a role in disease pathology. 
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Some diseases show changes to the development of myelin. Down syndrome patients 
show a similar overall pattern of myelination but have delayed development of myelin in the 
hippocampus, as well as impaired myelination in the corpus callosum (40,41). The long-term 
effects of developmental delays in oligodendrocyte differentiation and myelination are unclear. 
It is also uncertain if white matter changes are primary causes of these diseases or if they are 
secondary symptoms, caused by alterations to neurons. With many studies demonstrating the 
importance of white matter for functional neural circuits and alterations in diseases, it is clear 
that myelin plays an important role in neuronal health and development.  
 Dysmyelinating disorders. Dysmyelinating diseases are diseases that affect the 
development of myelin. These diseases include the leukodystrophies: disorders that affect the 
white matter of the CNS. A well-known leukodystrophy is the X-linked Pelizaeus Merzbacher 
Disease (PMD) characterized by hypomyelination, neurologic impairment and progressive 
decline (review (42)). PMD is caused by alterations to the Plp1 gene the encodes proteolipid 
protein in oligodendrocytes (43). Mutations in Plp1 can lead to overexpression of PLP1 or 
protein misfolding, causing protein aggregation, oligodendrocyte cell death and 
hypomyelination (44-46). The misregulation of Plp1, both gain and loss of function, leads to 
PMD and this pathology highlights the tight control necessary for proper oligodendrocyte 
development and myelination. No therapies currently exist for PMD, re-iterating the necessity 
to continue investigations into oligodendrocyte biology.  
Myelin in neural circuit function 
 Neural circuits require precise timing for functionality. This requires specific timing of 
input across variable distances and multiple sites. With evolution and expansion of the brain, 
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this timing requirement becomes increasingly complex (47,48). One method to alter conduction 
velocity is to change axon diameter. In unmyelinated axons, the conduction velocity is 
proportional to the square root of the axon diameter. Thus, increasing axon diameter increases 
conduction velocity (47,49). However, size constraints and energetic demands of large axons 
limit an organism’s ability to alter conduction velocity by modulating axon caliber. Vertebrates 
developed myelin as another mechanism to control conduction velocity (50).  
Multiple myelin parameters influence conduction velocity. Myelin increases membrane 
resistance, increasing the likelihood that ions will move down an axon rather than across the 
membrane. Increasing membrane resistance prevents current from leaking across the 
membrane. This allows for signal propagation at nodes of Ranvier, the space between myelin 
segments where voltage-gated sodium channels are clustered. Myelin thickness, myelin 
internode length, and nodal properties can all modulate conduction velocity and influence the 
timing of signal integration in neural circuits (Figure 1.2).  
Regulation of myelin parameters. Electron microscopy has been used to study myelin 
thickness by measuring the g-ratio, the ratio of the axon perimeter to the outer myelin 
perimeter. Early studies identified a theoretical optimal g-ratio of ~0.6 (47) while the 
experimental value is 0.7-0.8 in both the CNS and PNS (51-53). Many studies have identified 
pathways that regulate myelin thickness, including the AKT/mTOR pathway (54-57), the 
MEK/ERK pathway (58-60), and cytoskeletal pathways (61,62).  
More recently, investigations have identified myelin internode length as an important, 










Figure 1.2 Myelin parameters influence conduction velocity. Multiple parameters can 
influence conduction velocity. (A) Traditional models of myelinated axons are represented by 
uniformly myelinated axons. (B) Changing axon diameter alters conduction velocity changes. (C) 
Changes to myelin parameters, including changes in the distances between myelin internodes, 
differences in myelin sheath thickness or internode length also modulate conduction velocity. 
Functional neural circuits require precise timing of signals. Changing myelin or axonal 
parameters can alter when a signal reaches an integration center (D) to ensure integration and 
proper signal transduction. 
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impressive level of diverse myelination profiles. Pyramidal neurons in the cortex show various 
lengths of myelin internodes, as well as variations in gaps between myelin internode segments 
(66). Additionally, both white and gray matter tracks show heterogeneous lengths of nodes of 
Ranvier predicted to alter conduction speed by 20% (67). This suggests that distinct myelin 
profiles, including variations in myelin thickness, internode length and nodal properties 
function to coordinate precise conduction velocity (Figure 1.2).   
 Neuronal activity influences myelination. Multiple lines of evidence suggest that 
neuronal activity modulates myelin production in the CNS. One of the first investigations linking 
neuronal activity and oligodendrocyte development showed that decreasing action potential 
propagation in the optic nerve (a highly myelinated area) led to a decrease in OPC proliferation 
(68). Further studies used tetrodotoxin to block voltage-gated sodium channels, leading to a 
decrease in myelinated axons in both the PNS and CNS while increasing neuronal firing by α-
scorpion toxin increased myelin in vitro (69). Inhibiting vesicular release in vitro also decreased 
myelin protein synthesis while inhibiting K+ channels blocked myelin formation in spinal cord 
explants without altering axonal development (70,71). Additionally, low-frequency pulses 
downregulate cell recognition molecules (72). These data demonstrate that global changes to 
neural activity influences oligodendrocyte development and myelination.   
 With technological advances, it is becoming possible to modulate neural activity and 
individual neuronal subtypes. Multiple studies have taken advantage of this growing technology 
to alter neural activity both in vitro and in vivo. These studies show that neural activity 
influences which axons become myelinated as well as modulates distinct myelin parameters. In 
vivo data show that neuronal activity is not required for initiation of myelin wrapping but is 
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required for myelin sheath stabilization (73). Additionally, pharmacologically blocking synaptic 
vesicle release decreases the number of myelinated axons and the number of myelin sheaths 
produced per oligodendrocyte, while increasing neuronal activity increases the number of 
myelinated axons and myelin sheaths per oligodendrocyte (74). Similarly, neurons with 
increased firing are preferentially myelinated compared to less active neurons (75). 
Surprisingly, blocking synaptic activity on specific neuronal subtypes does not alter myelin 
patterns (76), highlighting the diverse mechanisms that modulate myelination. 
Neuronal activity is also known to modulate specific myelin parameters, as decreasing 
activity via monocular deprivation leads to a decrease in myelin internode length without 
altering myelin thickness (77). Decreasing glutamate receptor activity in oligodendrocytes 
phenocopies monocular deprivation, suggesting that oligodendrocytes incorporate information 
from axons that regulate myelin internode length (77). Altering neuronal activity also 
modulates animal behavior. In awake behaving mice, stimulating cortical projection neurons 
using channel rhodopsin led to increased OPC proliferation, oligodendrocyte differentiation, 
and myelin thickness. This stimulation also improved motor behavior (78). Together, these data 
demonstrate that neuronal activity promotes OPC proliferation, differentiation, myelin patterns 
and behavior.  
 Altering myelin parameters in functional circuits. Sensory integration systems require 
precise timing and synchrony for proper function. For example, in the auditory system specific 
timing and integration of sensory inputs are necessary for sound localization. In binaural 
hearing, the ability to hear with two ears, sound reaches each ear at different times called the 
interaural time difference (ITD). Sound will trigger action potentials at each ear that require 
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precise integration at coincident detector neurons in the medial superior olive (MSO) (79). 
Since sound reaches the two ears at different times, this means that each stimulus will initiate 
action potentials at different times. Thus, to reach the MSO at the same time, the action 
potentials must travel at different speeds. Investigations in the auditory brainstem show that 
variations in myelin internode length, nodal properties, and axon caliber are used to ensure 
precise timing of the stimulus at the integration center (64,65,80). Additionally, temporary 
sensory deprivation using earplugs led to hearing loss, slower conduction velocity, and 
decreased myelin thickness (81). Together, these data indicate that the auditory system shows 
remarkable heterogeneity in myelin profiles and both axonal and myelin parameters are used 
to modulate conduction velocity in systems that require precise temporal processing. 
Furthermore, myelination profiles require precise regulation for proper neural circuit function 
and alterations to myelin parameters have significant consequences on functional circuits.  
Myelin during learning. Learning complex tasks leads to an increase in oligodendrocyte 
density and myelination, while blocking oligodendrogenesis impairs motor skill learning (2,82). 
Additionally, social isolation leads to decreases in oligodendrocyte number and deficits in social 
development (83). Learning new tasks such as playing the piano or juggling lead to structural 
changes in white matter (84,85). Voluntary exercise also increases oligodendrogenesis (86). 
Together, this evidence emphasizes the importance of myelin in neural development and 
function.  
Signaling mechanisms that control oligodendrocyte development 
Oligodendrocyte development involves precise coordination of cellular movements, 
integration of signals from the cellular matrix, as well as interactions with neighboring 
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oligodendrocytes and neurons. There are multiple signaling pathways that are known to 
integrate extracellular information into the cell to coordinate this process. Two major pathways 
that positively regulate oligodendrocyte development are the phosphatidyl inositiol-3-
phosphate kinase PI3K/AKT/mTOR and extracellular signal-regulated kinases-1-2 (ERK1/2) 
signaling pathways. Both of these pathways are stimulated by growth factors, increase 
activation throughout oligodendrocyte differentiation (87-90) and act through different 
signaling cascades to coordinate oligodendrocyte development.  
AKT/mTOR pathway in oligodendrocyte differentiation and myelination. Platelet 
derived growth factor-a (PDGF) and insulin growth factor-1 (IGF-I) are growth factors required 
for oligodendrocyte development (91-93). PDGF and IGF can activate PI3K, leading to 
phosphorylation, and activation, of AKT at threonine 308 and serine 473. PI3K-AKT signaling 
promotes both proliferation and survival of OPCs (91,94). These signaling molecules are also 
important for later stages of development as constitutively activating AKT in oligodendrocytes 
leads to increased myelination throughout adult life (54). Follow up studies determined that 
AKT promotes myelination by modulating mTOR activity and mTOR promotes oligodendrocyte 
differentiation, myelin initiation and myelin thickness (95-98). Together, these data 
demonstrate that PI3K, AKT, and mTOR act in the same pathway as important regulators of 
oligodendrocyte development and myelination. 
mTOR promotes oligodendrocyte differentiation and acts in two distinct complexes 
(57,87-89,96). The two complexes contain some of the same proteins, including mTOR, DEPTOR 
(DEP domain containing mTOR-interacting protein), and GbL (mammalian lethal with SEC13 
protein 8), as well as some distinct proteins (99). mTORC1 is identified by the presence of the 
 14 
protein raptor while mTORC2 is identified by the presence of the protein rictor (for review, see 
(99,100). Of the two complexes, much more is known about mTORC1. It is known that both 
complexes promote differentiation but loss of mTORC1 leads to a greater phenotype than loss 
of mTORC2 (57,101). Although loss of mTORC2 alone leads to very mild phenotypes in vivo, 
genetic ablation of raptor and rictor simultaneously in oligodendrocytes leads to a greater 
decrease of myelin thickness than loss of raptor alone (57,102). This indicates that both mTOR 
complexes regulate oligodendrocyte development and may play redundant roles. Further 
studies determined that loss of mTORC2 in OPCs delays differentiation and myelination but 
eventually mTORC2 cKOs reach control levels (102). Additionally, loss of mTOR, raptor, or rictor 
in vitro leads to a decrease in MBP protein but only loss of mTOR or rictor, the protein involved 
in mTORC2 signaling, led to a decrease in mbp mRNA (88). These data suggest that mTORC1 
and mTORC2 both play an important role during oligodendrocyte differentiation and 
myelination and may act through multiple mechanisms. 
The individual mTOR complexes have different downstream targets. mTORC1 regulates 
protein translation by phosphorylating ribosomal S6 kinase or through the initiation factor 4E-
binding protein 1 (4E-BP1) (103). mTORC1 can also modulate lipid synthesis through the basic 
helix-loop-helix transcription factor sterol and regulatory element binding protein (SREB) (104-
106). SREB then modulates the transcription of genes required for fatty acid and cholesterol 
biosynthesis. Since myelin is roughly 70% lipid content, including galactosphingolipids, 
phospholipids, saturated fatty acids, and cholesterol, regulating the production of these lipids is 




Figure 1.3. Signaling pathways involved in oligodendrocyte differentiation and myelination. 
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Figure 1.3. Signaling pathways involved in oligodendrocyte differentiation and myelination. 
(A) Multiple signaling pathways regulate oligodendrocyte differentiation and myelination. BMP 
activity is schematized in purple. The BMP pathway is stimulated by BMP binding to BMP 
receptors, leading to kinase activity by the intracellular domain and phosphorylation of SMAD 
proteins. SMADs with interact with co-SMADs and translocate to the nucleus where they will 
initiate transcription of downstream targets such as ID1 and ID2 that inhibit oligodendrocyte 
differentiation. Growth factors can activate the AKT/mTOR pathway, schematized in green. 
Upon growth factor binding, receptor tyrosine kinases (RTKs) will activate PI3K, which will then 
activate AKT or mTORC2. mTORC2 will then phosphorylate AKTSer473 or target cytoskeletal 
rearrangement through PKCa or lipid metabolism via SGK. AKT will directly phosphorylate 
mTORC1 or indirectly activate mTORC1 by inhibiting the TSC1/2 complex, allowing Rheb to 
activate mTORC1, and promote lipid synthesis through SREB, ribosome biosynthesis through 
4E-BP or protein translation though S6K1 and RBS6, promoting oligodendrocyte differentiation 
and myelination. The ERK1/2 pathway, schematized in yellow, is also activated by growth 
factors. RTKs will phosphorylate Raf, leading to subsequent phosphorylation and activation of 
Ras, MEK1/2, ERK1/2, then p90 ribosomal S6 kinases (RSKS), and then S6RP, which modulates 
protein translation and promotes myelination and myelin maintenance. (B) A simplified model 
of the BMP, AKT/mTOR, and ERK pathways demonstrate areas where the pathways may 
crosstalk with one another, shown by dotted lines. 
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mTORC2 targets multiple downstream pathways, separate from mTORC1. mTORC2 can 
activate AKT through phosphorylation at AKTSer473, a site required for its full activation. mTORC2 
can also modulate cytoskeletal organization through protein kinase C (PKC) and rho GTPases or 
lipid metabolism through serum and glucocorticoid-induced protein kinase (SGK), independent 
of mTORC1 activity (109-112). The targets of mTORC2, AKT and the actin cytoskeleton, are 
required for oligodendrocyte differentiation and myelination, suggesting that mTORC2 may 
independently modulate oligodendrocyte development through both pathways. To fully 
understand how mTOR complexes functions, it will be necessary to determine the signaling that 
differentially activates each complex.  
The timing of AKT/mTOR pathway activation is crucial for precise coordination of 
cellular differentiation. In the peripheral nervous system, the AKT/mTOR pathway regulates 
Schwann cell differentiation and myelination and mTORC1 activity is highly regulated 
throughout this entire process. Surprisingly, hyperactivating mTORC1 activity before 
myelination initiation decreases the number of myelinated axons, but hyperactivation of 
mTORC1 after myelination initiation leads to hypermyelination (113). These data indicate that 
high mTORC1 function is required for radial sorting of axons in the PNS and that a subsequent 
decrease in mTORC1 activity is required for myelin initiation. They also demonstrate the 
requirement for tight timing of signaling pathways in myelinating cells. The precise timing of 
mTORC1 activation in the CNS may be similarly required but is undetermined. 
ERK1/2 pathway in oligodendrocyte differentiation and myelination. Mitogen-
activated protein kinases (MAPKs) are signaling pathways that convert extracellular signals to 
intracellular responses through multiple phosphorylation events. MAPKs are activated by 
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growth factors, including fibroblast growth factor (FGF), IGF, PDGF, among others (91,114,115). 
Upon stimulation, receptor tyrosine kinases phosphorylate Raf-1, which then phosphorylates 
MEK1/2, leading to subsequent activation of ERK1/2 and downstream targets such as p90 S6 
kinases (RSKs) and ribosomal protein S6 to promote protein translation (Figure 1.3) (116-118). 
In vitro data suggest that ERK1/2 promotes OPC survival but in vivo data demonstrate that 
genetically ablating ERK1 or ERK2 does not alter cell survival (58,119-122). These data indicate 
that ERK1/2 signaling is not required for oligodendrocyte cell survival in vivo. However, data 
clearly show that ERK1/2 positively regulates myelin production in the CNS. Loss of ERK1/2 
leads to a reduction in myelin thickness and loss of the downstream signaling molecule p-S6RP. 
Reciprocally, increasing MEK1/2, and ERK1/2 signaling increases myelin thickness without 
altering oligodendrocyte differentiation (58,59,121,123). The in vivo evidence strongly suggests 
that ERK1/2 signaling positively regulates myelination during later stages of oligodendrocyte 
development and is not required for early oligodendrocyte differentiation. 
Multiple research groups demonstrate that the AKT/mTOR and ERK1/2 pathways 
crosstalk. In the PNS, multiple growth factors (PDGF, IGF, neuregulin) stimulate both of these 
pathways but vary in the degree of activation, leading to differences in Schwann cell 
differentiation and myelination (124). These pathways also crosstalk during cardiac 
development and cancer (125-128). ERK1/2 phosphorylates and inactivates Tsc2, a negative 
regulator of mTOR (129). ERK1/2 can also phosphorylate raptor at multiple sites to increase 
mTORC1 activity (130,131). The signaling pathways also share the downstream target ribosomal 
protein S6 (S6RP) (116). However, ERK1/2 phosphorylates S6 at serines 235/236 through p90 
ribosomal S6 kinases (RSKs), while AKT/mTOR phosphorylates S6RP at multiple sites through 
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activation of p70 ribosomal S6 kinase (S6K1) (116,132). These data demonstrate AKT/mTOR and 
ERK1/2 pathways crosstalk at multiple levels throughout the signaling cascade to promote 
protein translation through S6RP (Figure 1.3).  
Multiple groups have shown that AKT/mTOR and ERK1/2 also crosstalk during 
oligodendrocyte development (59,87,133). In vitro and in vivo loss of mTOR activity in 
oligodendrocytes increases in ERK1/2 signaling, suggesting that these signaling pathways may 
coordinate with one another to regulate oligodendrocyte development (87). Constitutively 
activating AKT in vivo can only partially rescue loss of ERK1/2. Activating AKT after loss of 
ERK1/2 significantly increases both myelin thickness and downstream signaling (p-S6RP, p-
70S6K, p-mTOR) but not quite to WT levels. This suggests that the AKT/mTOR pathway can 
moderately compensate for loss of ERK1/2 signaling. However, constitutively activating PI3K 
(upstream of AKT) can fully rescue the myelin phenotype after loss of ERK1/2 (59). This 
indicates that PI3K can compensate for loss of ERK1/2 signaling through both AKT dependent 
and AKT independent mechanisms. These data indicate the AKT/mTOR and ERK1/2 pathways 
share some similar functions but are not interchangeable, as ERK1/2 cannot rescue loss of 
mTOR in early stages of oligodendrocyte differentiation (59). Together, these data show that 
both the AKT/mTOR and ERK1/2 pathways are positive regulators of CNS myelination and that 
these pathways crosstalk to coordinate this process.   
BMP signaling in oligodendrocyte differentiation and myelination. One of the negative 
regulators of oligodendrocyte differentiation is the family of bone morphogenetic proteins 
(BMPs). BMPs are a member of the TGF-b superfamily and known regulators of nervous system 
development. BMPs are highly expressed in the dorsal portion of the vertebrate spinal cord and 
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decrease in a gradient fashion down to the ventral spinal cord (134,135). Addition of soluble 
BMP early in the oligodendrocyte lineage to in vitro cultures led to a change in cell fate with an 
increase in astrocyte number and a decrease in differentiated oligodendrocytes. In reciprocal 
experiments, inhibiting BMP led to an increase in differentiated oligodendrocytes (136,137). 
The role of BMP is specific to early stages of oligodendrocyte differentiation as manipulating 
BMP in mature oligodendrocytes in culture had no effect on cell morphology or membrane 
production (137). 
 In vivo data also demonstrate that increasing BMP inhibits oligodendrocyte 
differentiation but studies differ in whether there is a change to astrocyte number. Grafting 
cells that overexpress human BMP2 in chick neural tube decreases the number of differentiated 
oligodendrocytes without altering astrocyte cell number (138). In Xenopus and rodent explants, 
exogenous BMP also inhibits oligodendrocyte differentiation (139). Similarly, overexpression of 
BMP4 in neurons appears to increase astrocyte differentiation and decreases oligodendrocyte 
differentiation (140). These data indicate that BMP in the extracellular environment modulates 
oligodendrocyte differentiation. Later experiments specifically altered BMP signaling in the 
oligodendrocyte lineage, showing that loss of the BMP receptor BMPr1a in oligodendrocytes 
leads to a decrease in cell cycle rate and an increase in the number of mature oligodendrocytes 
without altering astrocyte of neuronal cell numbers (141). Together, these in vitro and in vivo 
data demonstrate that BMP negatively regulates oligodendrocyte differentiation. 
Although BMP is known to inhibit oligodendrocyte differentiation, the source of BMP 
secretion is unknown. Additionally, it is unclear what other factors regulate BMP signaling. 
Intriguingly, in vitro data show that mTOR may regulate BMP signaling. Pharmacologically 
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inhibiting mTOR using the drug rapamycin leads to a decrease in myelin gene expression and an 
increase in downstream BMP targets ID2 and ID4 (88). These data suggest that the AKT/mTOR 
pathway may interact with the BMP pathway to coordinate oligodendrocyte development 
(Figure 1.3).   
Cytoskeletal regulation of myelinating cells. 
The cytoskeleton provides both structure and function, acting as a mechanism for cell 
motility and as a skeletal framework defining cell morphology. For example, in migrating 
epithelial cells, the actin cytoskeleton consists of a dense meshwork of filamentous actin and its 
regulators, which control actin filament turnover at the leading edge of a cell, thereby driving 
cellular movement.  
With recent advances in imaging techniques, there is more detailed understanding of 
the cytoskeletal architecture of cells in the nervous system. Investigations into neural cell types 
provide novel insights and hypotheses regarding neuron-glia interactions. Periodic cytoskeletal 
patterns of actin and spectrin, an actin binding protein, are found in multiple cell types of the 
nervous system. These patterns are found in both inhibitory and excitatory neurons, as well as 
differentiating oligodendrocytes. Surprisingly, astrocytes or microglia do not contain the same 
cytoskeletal periodicity, suggesting cell-type specific cytoskeletal patterns (142). The 
cytoplasmic cytoskeletal periodicity of oligodendrocytes differs from epithelial cell cytoskeletal 
networks and appears to act as a scaffold to mediate cell-cell interactions. In oligodendrocyte-
axon interactions, these cytoskeletal patterns generally align with one another and may be 
mediated through specific cell adhesion molecules such as L1CAMs (143). These data suggest 
that the cytoskeleton is tightly regulated in myelinating cells. How are these patterns 
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determined? Are these patterns an intrinsic pattern of the cell or are there extracellular signals 
mediating the formation of these cytoskeletal patterns?  
Cytoskeleton in myelinating cells.  
Modulation of cytoskeletal organization is required for oligodendrocyte precursor cells 
(OPC) movement during development, when these cells migrate to their appropriate 
destination and differentiate to mature oligodendrocytes, the myelinating cells of the CNS. 
There, they respond to axons by extending massive amounts of differentiated plasma 
membrane to ensheath the axon and generate myelin, thereby allowing for increased action 
potential propagation along the axon, as well as metabolic support to axons (1,73,74,144) .  
In the peripheral nervous system (PNS), myelin is formed by Schwann cells. Neural crest-
derived Schwann cell precursor cells migrate to the periphery where they proliferate and move 
along axons until they reach their final destination at which point they surround bundles of 
axons. Schwann cells develop a basal lamina, and begin radial sorting of axons, where they 
separate out large caliber axons, generating  a 1:1 relationship with them, and begin 
myelination (145) (146). Although oligodendrocytes and Schwann cells are derived from 
different tissues, they share major similarities in the drastic morphological changes required for 
myelination that necessitate changes to the cytoskeleton.  
Actin cytoskeletal dynamics are a major element driving myelination. Recent discoveries 
highlight the role of actin polymerization during OPC process extension and of actin filament 
retraction and depolymerization driving myelin wrapping (61,62). Filamentous actin (F-actin) is 
found in OPCs and OPC processes, but both in vitro and in vivo models show that F-actin is 
absent from compact myelin except for the outermost myelin layer and the leading edge 
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(61,62,142). Two hypotheses arise from these data. One proposes that during myelination, 
actin polymerization at the leading edge, the inner tongue of myelin, is the driving force 
promoting myelin wrapping, while actin depolymerization immediately behind the leading edge 
allows for myelin compaction (62). The second hypothesis suggests that actin depolymerization 
provides the force to drive myelin wrapping (61,62). Both hypotheses require a tightly-
regulated, localized signal(s) that could rapidly switch from actin polymerization to actin 
depolymerization. That signal is yet to be determined as technical limitations have constrained 
high-resolution visualization of actin polymerization at the leading edge in vivo. In vivo models 
of myelin cytoskeleton phenotypes are summarized in Table 1. The question remains, what 
regulates the cytoskeleton during cellular differentiation and myelination? 
Actin polymerization in myelinating cells.  
Myelinating cells in both the CNS and PNS express actin polymerizing proteins, including 
members of the Arp2/3 complex, N-WASP and WAVE proteins (147), which are also found in 
myelin sheath preparations. In oligodendrocytes, WAVE1 is the predominate actin polymerizing 
protein, whereas in Schwann cells, WAVE2 is the major protein (147). Thus, PNS and CNS 
myelinating cells share similar but distinct molecular players. Both cell types also express the 
family of Rho GTPases, which transmit signals from membrane receptors to the cytoskeleton 
(148). Rho GTPases regulate signal transduction by acting as molecular switches-quickly 
alternating between on/off signals- through their rapid change between their GTP bound 
(active) state and GDP bound (inactive state) (149). The most studied Rho GTPases are RhoA, 
Cdc42, and Rac1. RhoA activates ROCK to regulate stress fiber formation, while Cdc42 and Rac1  
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Table 1.1 Myelin cytoskeleton phenotypes in in vivo animal models. 
Abbreviations: ON: optic nerve, CC: corpus callosum, SC: spinal cord, EAE: experimental 
autoimmune encephalomyelitis 
Cnp-Cre and Olig2-Cre are used for early promoters in the CNS. Plp-CreERT is used for a late 
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activate N-WASP and WAVE proteins, which promote actin nucleation through activation of the 
Arp2/3 complex (150). 
In the CNS, in vitro data demonstrate that Cdc42 and Rac1 are positive regulators of OPC 
morphological differentiation-the change from a simple bipolar morphology to cells with 
multiple complex processes. RhoA acts in opposition as a negative regulator of process 
extension (151). Loss of Cdc42 or Rac1 does not prevent OPC migration or differentiation in 
vivo, but loss of these GTPases leads to a unique myelin phenotype. Specifically, loss of Cdc42 
or Rac1 leads to enlargement of the inner tongue and double knockouts suggest that Cdc42 and 
Rac1 act synergistically to regulate myelination (152). In the PNS, comparable GTPases regulate 
Schwann cell proliferation, radial sorting, and myelination. Cdc42 primarily regulates Schwann 
cell proliferation while Rac1 promotes Schwann cell lamellipodia formation (153). Conditional 
knock out of Rac1 also results in delayed axonal sorting and hypomyelination (154). Rac1, but 
not Cdc42, is regulated by AKT in the PNS, where hyperactivation of AKT in Schwann cells leads 
to increased myelin thickness. Inhibition of the AKT/mTOR pathway via the mTOR inhibitor 
rapamycin rescues hypermyelination in the CNS (95,155) but not the PNS (155), suggesting that 
AKT regulates myelination both through mTOR and Rac1 pathways. 
Loss of known targets of these GTPases also impairs OPC development. Loss of the actin 
nucleator WAVE1 leads to a decrease in the number of OPC processes, as well as 
hypomyelination, quantified by the number of myelinated axons in the corpus callosum and 
optic nerve. Mice lacking WAVE1 also have decreased Na+ and K+ channel clustering in the 
optic nerve (156). Surprisingly, loss of WAVE1 in the spinal cord does not change the number of 
myelinated axons.  Another downstream target of GTPases, ArpC3, a molecule that promotes 
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actin nucleation, is a positive regulator of OPC morphological differentiation. When ArpC3 is 
lost before myelination, there is a decrease in the number of myelinated axons in the optic 
nerve but its loss during myelin wrapping does not impact myelination (61). Thus, this study 
would suggest that actin polymerization is required for OPC process extension and initial axon 
ensheathment but is dispensable during myelin wrapping. 
Similarly, downstream GTPase targets also regulate PNS myelination. One of the 
downstream targets, the actin nucleator N-WASP, is required for proper PNS myelination. 
Specifically, loss of N-WASP in Schwann cells leads to a decrease in the number of myelinated 
axons up to P60, and the myelin that is produced is significantly thinner than WT myelin, with 
shorter internodes. These data suggest that N-WASP is important for the longitudinal extension 
of myelin, or myelin internode length (157,158). Another Rho GTPase target is Profilin1 (Pfn1). 
Pfn1 promotes actin polymerization by binding to actin monomers and promoting 
polymerization through the exchange of actin-bound ADP to ATP (159,160). Montani and 
colleagues demonstrate that Pfn1 promotes radial sorting and myelination and is regulated by 
Rho/ROCK signaling (161). These data from both the PNS and CNS indicate that Rho GTPases 
and their downstream targets are required for proper cell differentiation and myelination 
(Figure 1.4). There are also cytoskeletal components not necessarily associated with GTPases 
that are important regulators of the cytoskeleton. For example, junction mediating and 
regulatory protein, Jmy, has recently been shown to regulate oligodendrocyte differentiation. 
In an elegant experiment, Azevedo and colleagues isolated OPC soma and early OPC membrane 
protrusions in rat primary OPCs, to undertake transcriptomics to characterize mRNAs 
translocated to OPC/differentiating oligodendrocyte processes. The investigators identified Jmy 
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Figure 1.4. Predicted cytoskeletal signaling pathways at the leading edge of myelinating cells. 
(A) The leading edge of an OPC process is the cytoplasmic rich expansion that comes into 
contact with an axon, which then becomes the inner tongue during myelin wrapping. The inner 
tongue remains in close contact with the axon as it ensheaths the axon and continues to wrap 
during active myelination. RhoGTPases Rac1 and Cdc42 signal through WAVE or N-WASP and 
then the Arp2/3 complex to promote actin polymerization. RhoGTPases can also signal through 
the PAK proteins to phosphorylate LIMK, that then phosphorylates and inactivates cofilin to 
regulate actin turnover. Active (unphosphorylated) cofilin binds to f-actin, induces a local twist 
in the filament, leading to actin  severing. High levels of cofilin bound to f-actin can induce 
twisting throughout the entire filament, changing cofilin activity to an actin stabilizing protein. 
(B) Longitudinal view of a myelinated axon with areas of open cytoplasmic channels that close 
with myelin compaction. (C) Cross section of myelinated axon. F-actin localizes to cytoplasmic 




as one of the mRNAs enriched in the newly formed processes, which increases expression 
during CNS myelination. Loss of Jmy results in decreased OPC morphological differentiation that 
is dependent on F-actin assembly. Thus, they conclude that Jmy is a novel regulator of OPC 
differentiation through actin modulation (162). Similarly, CamKIIb promotes OPC morphological 
differentiation, and its loss results in thinner myelin. However, specifically inhibiting the kinase 
activity of CamKIIb in vivo does not alter myelination. This suggests that CamKIIb may regulate 
OPC morphological differentiation independent of its kinase activity, potentially through its 
actin binding domain (163). 
  OPCs are highly dynamic in their membrane extension and retraction and they make 
myriad connections with axons. However, only some of these processes remain in place and 
produce stable myelin sheaths (73), leading to the question of the regulation of process 
stabilization vs retraction during myelination. Thus, further investigation is needed into the cell 
biology of OPC process retraction. While it is well established that actin polymerization is 
required to extend OPC processes, what are the signals that regulate OPC process retraction? Is 
there a local decrease in actin polymerization factors or local activation of actin depolymerizing 
factors at the leading edge? Evidence of local control of actin polymerization exists in other 
systems. For example, in the PNS, exposure of Schwann cells to low levels of hydrogen peroxide 
triggers local translation of cytoskeletal regulators such as Annexin2 (164). Local translation and 
phosphorylation of Annexin2 accompanies significant cytoskeletal reorganization and Schwann 
cell polarization (164). It is likely that local signaling from the environment, from axons or 
interacting neurons, may promote local translation of cytoskeletal regulators that alter actin 
polymerization and myelination.  
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Actin depolymerization in myelinating cells.  
In addition to actin polymerization, actin depolymerization is a crucial element driving 
myelination. Early downregulation of actin depolymerizing proteins including cofilin and 
gelsolin allow for OPC morphological differentiation (165). Surprisingly, exposure to the actin 
depolymerizing agent LatrunculinA during late differentiation in vitro increases oligodendrocyte 
membrane production (61,62). Consistent with this positive impact of actin depolymerization, 
loss of the actin severing proteins ADF and cofilin1 in vivo inhibits myelination. Importantly, this 
increases the size of the inner tongue, suggesting that actin depolymerization regulates the size 
of the inner tongue to drive myelin wrapping (62). One actin depolymerizing protein is cofilin, 
and one suggested model of myelination proposes that MBP competes with cofilin for binding 
to phosphatidyl inositol 4,5 bisphosphate, PIP2. The more MBP outcompetes cofilin and binds 
to PIP2, the more cofilin is released into the cytoplasm where it acts to depolymerize actin and 
thereby drive myelin wrapping (61). In Schwann cells, cofilin is downstream of neuregulin 
(Nrg1) signaling. It is recruited to the leading edge after stimulation with Nrg1 in vitro, and is 
required for normal Schwann cell-axon interactions and proper myelination in vivo (166).  
It must be noted that the role of cofilin in myelination is potentially quite complex. The 
ratio of activated (unphosphorylated) cofilin to actin influences cofilin activity. Active cofilin 
binds to F-actin, inducing a twist to the filament, which leads to actin severing. However, if high 
levels of cofilin bind to F-actin, this can induce a twist throughout the entire filament and act as 
an actin filament stabilizing agent (167). It will be informative to determine the localization of 
cofilin within the myelin sheath. Does activated cofilin localize to the inner tongue? 
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Investigating the ratio of cofilin to actin will also inform the function of cofilin during myelin 
sheath formation.  
  Another major actin depolymerizing protein is gelsolin, a calcium-sensitive protein that 
severs filamentous actin (168). Importantly, gelsolin is expressed in both oligodendrocytes and 
Schwann cells (169). In vitro, gelsolin is expressed in oligodendrocyte cell bodies and in 
cytoplasmic processes but not in the membrane sheets (170). In vivo, gelsolin is expressed in 
compact myelin and is specifically enriched at the node of Ranvier (169). Gelsolin protein 
expression in the forebrain increases during development reaching a peak between 20-30 days, 
coincident with increasing MBP expression. However, gelsolin expression in the forebrain starts 
to decrease while MBP expression continues to increase and both gelsolin and MBP are 
expressed in compact myelin (169). Gelsolin regulates myelin wrapping in the optic nerve as 
loss of gelsolin leads to a small decrease in myelin thickness without altering axon caliber (61). 
Given the observation that multiple depolymerizing factors are highly expressed in myelinating 
oligodendrocytes (171), it is possible that gelsolin is one of several actin regulators. This 
redundancy would ensure proper regulation of the actin cytoskeleton during myelin wrapping. 
Overall, these data indicate that expression of actin depolymerizing factors such as cofilin and 
gelsolin play an important role during OPC differentiation and myelination.  
P21-activated kinases.  
One family of molecules that can regulate the switch between actin polymerization and 
depolymerization is the family of P21-activated kinases (PAKs). PAKs are small molecule 
serine/threonine kinases implicated in several diseases, including multiple cancers and 
schizophrenia, as well as cortical development (172-174). PAKs are divided into two groups, 
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Group I PAKs (PAK1-3), share a high degree of homology and are more studied than Group II 
PAKs (PAK4-6). PAK activity depends greatly on their upstream activators. GTPases are known 
activators of PAKs that promote PAK regulation of the actin cytoskeleton (175-177). When a 
GTPase binds to PAK, this induces a conformational change, releasing PAK from its 
homodimerization state, causing autophosphorylation, and subsequent PAK activation. PAK can 
then phosphorylate Lim kinase (LIMK), which then phosphorylates and inactivates the actin-
severing protein cofilin (178). However, PAKs may also be directly activated by PI-3 kinase, and 
PAK then directly phosphorylates actin, resulting in cytoskeletal rearrangement (177), further 
demonstrating that PAK function depends on the mechanisms of its upstream activation. 
PAKs are intriguing regulators because in addition to their relatively direct impact on the 
structure of the actin cytoskeleton. PAKs also regulate signaling pathways that regulate 
oligodendrocyte development and myelination, including the AKT and MAP kinase (MAPK) 
pathways. For example, PAKs can directly phosphorylate MEK1, driving the MAPK pathways 
(179,180). Additionally, while PAKs are kinases, in some cells they can regulate the AKT pathway 
through kinase-independent mechanisms. For example, Higuchi and colleagues demonstrate 
that PAK1 acts as a scaffold for AKT so that AKT can be translocated to the membrane and 
subsequently activated by 3-phosphoinositide-dependent kinase 1 (PDK1) (181).  
Mice with global loss of PAK1 and PAK3 have impaired postnatal brain growth, although 
the double knockouts are born with normal neonatal brain sizes. The adult double knockout 
mice show altered behaviors, including increased travel distance in open field tests and 
increased latency to platform in the water maze test. These behaviors likely result from altered 
neuronal function as animals have decreased neuronal dendritic complexity. Interestingly, they 
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also have a decrease in myelin production, indicating that PAK1 and PAK3 may be important for 
myelin production (182). Maglorius Renkilaraj and colleagues show that PAK3 is highly 
expressed early in OPC development and decreases with differentiation; in a model with global 
loss of PAK3, they show that PAK3 regulates OPC differentiation. In cultured PAK3-deleted 
OPCs, the loss of PAK3 does not change OPC morphology, migration or proliferation but does 
decrease OPC differentiation. By P14 in vivo, PAK3 KO mice have a reduced number of 
myelinated axons in the corpus callosum, but by adulthood there is recovery, as the number of 
myelinated axons are found. This suggests that mice can compensate for the loss of PAK3 (183); 
for example, other PAK family members may be able to compensate for loss of one PAK. PAK1 is 
also expressed in OPCs and its activated form, phospho-PAK1/2 is expressed in both the 
cytoplasm and in OPC processes (Figure 1.5). Thus, multiple PAK family members may be 
important for oligodendrocyte development. 
Fine tuning of PAK function is important for myelination, and thereby axonal function. A 
model of peripheral neuropathy exemplifies the important role PAK plays in proper myelin 
formation and function. In a mouse model of hereditary neuropathy with liability of pressure 
palsies (HNPP) generated by heterozygous deletion of Pmp22, the compound muscle action 
potential amplitude is decreased with no axonal loss, which suggests that the change in action 
potentials may result from changes in myelin. Indeed, myelin is somewhat decompacted with 
increased F-actin at the paranodes, accompanied by an increase in PAK1 and increased 
MEK1S298 phosphorylation in the sciatic nerves. Importantly, PAK inhibition decreased the F-








Figure 1.5 PAK1 is expressed in rat OPCs. A) Blue labels the oligodendrocyte lineage marker 
Olig2, green labels PAK1, and magenta labels the oligodendrocyte lineage marker NG2. Arrows 
point to PAK1 expression in the cytoplasm of the cell body and into the OPC processes. B) 
pPAK1/2 is expressed in rat OPCs. Blue labels the oligodendrocyte lineage marker Olig2, green 
labels pPAK1ser144/pPAK2ser141, and magenta labels NG2. Arrows point to pPAK1/2 expression in 
the cytoplasm of rat OPCs in the cell body and into the OPC processes. Scale bars are 25µM. 
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These studies in both the CNS and PNS indicate that the PAKs play a role in myelination 
and that fine-tuning PAK activity is important for proper myelination, as either loss or 
overactivity of PAKs can cause abnormal myelin phenotypes. PAKs can regulate multiple 
signaling pathways important for oligodendrocyte development, including the cytoskeleton 
pathway through LIMK and cofilin as well as the AKT and ERK pathways. Additionally, there are 
multiple drugs available that target the PAK pathway. It will be important for future 
investigations to determine the cell-specific role for the PAK family members. 
Cytoskeleton involvement in adult myelin function.  
As our knowledge of the oligodendrocyte cytoskeleton increases, it provides insights 
into investigations of known regulators of the oligodendrocyte development program and their 
novel interactions with the cytoskeleton. Clearly the cytoskeleton is important in developing 
and actively myelinating oligodendrocytes. One of the proteins required for proper myelination, 
CNP, is present in CNS myelin and recent data suggest its interaction with F-actin may impact 
cytoplasmic openings in the myelin (185). Cytoplasmic openings remain present in mature CNS 
myelin, reminiscent of Schmidt-Lanterman incisures (SCIs) of the PNS, where F-actin is localized 
(186,187), and they may allow for increased transport within myelin between the 
oligodendrocyte soma and axon.  Although loss of CNP1 does not grossly alter CNS myelination 
or myelin structure, it eventually leads to axonal swellings, progressive motor deficits, and 
premature death (5). Snaidero and colleagues suggest that CNP normally antagonizes the 
compaction of CNS myelin by MBP, by interacting with F-actin directly, increasing actin 
bundling, and this maintains cytoplasmic openings within myelin, thereby allowing 
communication to the axon (185). This suggests that in addition to its role during myelination, 
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F-actin plays an important role in adult myelin by maintaining cytoplasmic openings in 
uncompacted myelin domains (Figure 1.4). Important questions remain as to what signaling 
molecules determine F-actin localization, and whether other myelin proteins promote F-actin 
stabilization or disassociation. 
Cytoskeleton in disease states.  
Intracellular and extracellular cytoskeletal changes occur in multiple diseases. After CNS 
damage such as diphtheria toxin-induced oligodendrocyte death or experimental autoimmune 
encephalitis (EAE), a mouse model of multiple sclerosis, oligodendrocytes increase cytoskeletal 
b-actin gene expression (188). In the shiverer mouse, there is increased F-actin in myelin 
(61,62). Thus, CNS injury leads to changes in the cytoskeleton, both an increase in F-actin and a 
decrease in actin depolymerizing factors.  
Cytoskeletal changes also occur with PNS injury. After sciatic nerve injury, Schwann cells 
increase expression of Cdc42. In this injury context, Cdc42 promotes SC proliferation and 
migration through the Wnt/b-catenin and p38 MAPK pathway (189). In the Trembler J mouse, a 
model for Charcot Marie Tooth (CMT) that contains a single point mutation in the pmp22 gene, 
F-actin localization remains unchanged, but there is increased F-actin accumulation at the 
nodes of Ranvier and Schmidt-lanterman incisures (190). In a mouse model of HNPP, where 
compression can induce injury in the peripheral nerve, F-actin organization is changed and 
impairs SC migration. This model also causes loss of Schmidt-lanterman incisures and abnormal 
accumulation of F-actin within myelin, as well as decreases in myelin internode length (191). 
Mutations in frabin/FGD4, a guanine nucleotide exchange factor that promotes Cdc42 activity 
by stimulating the exchange of GDP for GTP, also leads to PNS demyelination in patients with 
 37 
CMT. Specifically, these mutations lead to myelin outfoldings (192). These data indicate that 
changes to cytoskeletal regulators lead to disease states but that disease states also induce 
changes in the actin cytoskeleton in the PNS. 
Changes in cytoskeleton also lead directly to changes in signaling pathways. Recent data 
also suggest that specific signaling molecules, including a member of the linker of 
nucleoskeleton and cytoskeleton (LINC) complex, SYNE1, can transduce mechanical stimulation-
such as changes in the cytoskeleton- to the nucleus. SYNE1 can bind actin with its N-terminal 
domain and bind nuclear proteins with its C-terminal tail, therefore sensing changes in actin 
after mechanical stimulation to induce heterochromatin changes and OPC differentiation (193). 
This may provide a mechanism for mechanosensation in OPCs since mechanical stiffness 
influences OPC cell survival, proliferation, migration and differentiation (194). Additionally, 
mechanical strain decreases OPC proliferation and increases OPC differentiation by changing 
nuclear shape, chromatin organization and gene expression (195).  This is important because 
multiple sclerosis patients show decreased viscoelasticity (stiffness) compared to age and sex 
matched controls (196) while in cuprizone-induced demyelination, the corpus collosum shows 
reduced viscoelasticity compared to WT controls (197). Patients with other diseases associated 
with white matter abnormalities, such as Alzheimer’s disease (AD), also show decreased brain 
stiffness (198). Together, these data demonstrate that CNS injury induces changes to brain 
viscoelasticity, that changes in brain stiffness can alter OPC development, and that OPCs can 
sense changes to the actin cytoskeleton that can alter differentiation.  
There is much to learn about the cell biology of myelination. The field is rapidly 
increasing its understanding of the cytoskeleton throughout differentiation and myelination, 
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yet there is much more to investigate. It will be useful to determine whether the cytoskeleton 
provides the force pushing cytoplasm laterally to increase myelin internode length and where 
the cytoskeletal proteins, such as actin polymerizing/depolymerizing proteins, RhoGTPases and 
PAKs, localize in OPC branches (Figure 1.5), where they are localized in Schwann cells, and 
whether/where they localize within the myelin sheath.  
Many questions remain, for example, how does the cytoskeleton maintain cytoplasmic 
channels? How is information transmitted from the inner tongue of the myelin sheath to the 
cell body? Is there local translation of actin regulators at the inner tongue or are there small 
molecules that can act as molecular switches to rapidly regulate the change from actin 
polymerization to actin depolymerization at the leading edge? The cytoskeleton of myelinating 
cells is an amazingly complex structure with myriad functions-providing structure, motility, and 
signaling throughout normal development, in the normal adult nervous system and in disease 
pathology. Increasing our knowledge of the fundamentals of oligodendrocyte and Schwann cell 
biology will improve our understanding of neural development and function.  
Comparing developmental myelination and remyelination. 
Remyelination is an important, challenging goal of numerous therapeutics. The 
recapitulation hypothesis predicts remyelination is a recapitulation of developmental 
myelination (199). Indeed, multiple lines of evidence indicate that similar mechanisms 
modulate both myelination models. Developmental myelination and remyelination share a 
comparable goal: to wrap myelin membrane around axons. Both paradigms require the 
recruitment of OPCs, differentiation of myelinating oligodendrocytes, and targeting appropriate 
axons to ensheath with myelin (199-201). Many of the same transcription factors such as olig2, 
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nkx2.2, and sox2 are re-activated during remyelination (200,202,203). Similar mitogens are also 
involved in remyelination (204-206). Some of the negative regulators of differentiation and 
myelination, LINGO-1 and BMP, also inhibit remyelination (207,208). These data clearly 
demonstrate that there are some similarities between developmental myelination and 
remyelination. 
Despite these similarities between the two paradigms, considerable differences exist. 
During developmental myelination, axon caliber correlates with myelin thickness while in 
remyelination, myelin thickness is more uniform across multiple axon calibers (209,210). 
Signaling pathways that promote myelin wrapping during developmental myelination do not 
necessarily influence myelin wrapping during remyelination. For example, loss of PTEN, a 
negative regulator of the AKT pathway, increases myelin thickness during development but 
does not increase thickness during remyelination (56). Loss of TSC1, a negative regulator of 
mTORC1, leads to hypomyelination during developmental myelination. In a lysolecithin model 
of demyelination, loss of TSC1 in NG2+ OPCs increases myelination while loss of TSC1 in PLP+ 
OPCs inhibits remyelination (201). Surprisingly, glial stem cells produce both oligodendrocytes 
and Schwann cells that each contribute to remyelination in the CNS (211), further contributing 
to the differences between these two situations.  
Myriad factors could explain these differences. The local environments in each situation 
are distinctive. One of the most obvious differences is that during remyelination, there is often 
myelin debris in the local environment caused by degradation of myelin. In rodent models, 
addition of myelin debris to demyelinated lesions inhibits remyelination (212,213). 
Demyelination also induces multiple inflammatory responses, including the presence of 
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microglia and macrophages (214,215). Age is another factor that may contribute to differences 
between developmental myelination and remyelination. Remyelination capacity decreases with 
age (216). Are the local factors that are no longer present in older environments or ones that 
increase with age?  Are there inhibitory factors absent from development that inhibit 
remyelination? Investigating basic development of oligodendrocyte biology will be critical to 
increase our understanding of these cells. As we learn more about the intrinsic and extrinsic 
signals that regulate oligodendrocyte differentiation and myelination, the signals that 
differentiate disease states that require remyelination and normal developmental myelination 
will become apparent. Ideally, these differences will provide more opportunities to develop 
therapeutic targets for demyelinating and dysmyelinating diseases. 
Thesis summary 
The studies presented here focus on signals that regulate developmental myelination. 
Specifically, the data included add new insight into signaling pathways that modulate 
myelination in the CNS. Using both in vivo and in vitro methods, the findings included add new 
insight into the mechanism of AKT regulation of oligodendrocyte differentiation and 
myelination. Specifically, these studies show that increasing AKT activity in oligodendrocytes 
increases expression of the cytoskeletal regulator, PAK1. They further demonstrate that PAK1 
positively regulates oligodendrocyte morphological differentiation through the actin 
cytoskeleton and the amount of myelin production in an oligodendrocyte-specific manner by 
modulating myelin internode length. The data presented here also determine the mechanisms 
by which the AKT/mTOR pathway modulates oligodendrocyte differentiation and myelination 
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ROLE OF PAK1 DURING OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION 
Introduction 
 Polarized membrane production is a complex biological task. In the central nervous 
system (CNS), oligodendrocytes produce massive amounts of polarized plasma membrane as 
they generate myelin that wraps around axons. Myelin provides an insulating sheath that 
facilitates axon conduction velocity and provides metabolic support to axons (144,217). 
Oligodendrocytes must integrate signals from the extracellular environment, nearby cells, and 
the axons themselves to determine how much myelin to produce (73,74,218,219). Recent data 
highlight the complex role of the actin cytoskeleton throughout oligodendrocyte development. 
Actin polymerization is required for oligodendrocyte precursor cell (OPC) migration as they 
extend and retract filopodial-like processes, integrating signals from the surrounding 
environment (61,62,151). OPCs then differentiate into oligodendrocytes where they contact an 
axon and begin producing myelin. Myelin wrapping, the process of extending membrane 
around an axon, is driven by the cycle of actin polymerization and depolymerization at the inner 
tongue, also known as the leading edge, of the myelin wrap(61,62). Recent data indicate that F-
actin localizes to the leading edge during myelin wrapping, expanding the cytoplasm that 
protrudes underneath previous myelin wraps and between those wraps and the axon, driving 
membrane around the axon. F-actin is immediately depolymerized, allowing for myelin 
compaction in the region behind the leading edge (62). The signals that regulate cytoskeletal 
dynamics during oligodendrocyte differentiation and myelination are unknown. 
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The signals that regulate myelin production by oligodendrocytes have been intensively 
investigated. Most studies define myelin production by myelin thickness or the number of 
myelinated axons. Some of the major signaling pathways known to positively regulate myelin 
thickness include the AKT/mTOR and the MEK/ERK pathways, as well as modulators of the actin 
cytoskeleton. Conditional knockouts of the AKT/mTOR or the MEK/ERK pathways decrease 
myelin thickness, while activating these pathways increases myelin thickness 
(54,58,59,95,96,101,121). Altering actin cytoskeletal dynamics by increasing actin 
depolymerization increases myelin thickness (61), while conditionally deleting ADF/cofilin, an 
actin-depolymerizing protein, leads to a decrease in myelin thickness (62). Together, these 
studies establish that each of these pathways regulates myelin thickness, but little is known 
about how they affect myelin internode length. Additionally, less is known about the regulation 
of the actin cytoskeleton during myelination, compared to the AKT or ERK signaling pathways.   
 The p21-activated kinase (PAK) family of signaling molecules regulates multiple signaling 
pathways, some of which are involved in myelination. These serine/threonine kinases known to 
act both upstream and downstream of multiple pathways, including the AKT/mTOR, MEK/ERK, 
and cytoskeletal pathways, each of which regulates oligodendrocyte development and 
myelination (179-181). The PAKs are divided into two functional groups with Group I PAKs 
(PAK1-3) sharing a high degree of sequence identity within the group. These are characterized 
by a Cdc42/Rac1 interacting binding (CRIB) domain (175-177).  Group II PAKs (PAK4-6) are more 
variable and they do not contain the CRIB domain. Of the Group I PAKs, PAK3 is expressed 
predominately in the brain and recent data indicate that PAK3 regulates oligodendrocyte 
differentiation and myelination (220,221). Huang and colleagues demonstrated that a global 
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knockout of PAK1 and PAK3 led to decreased total myelin production in the brain, suggesting 
that PAK1 or PAK3 may be important for myelination (182). While PAK3 has been shown to be 
required for OPC differentiation and its loss leads to a decrease in myelinated axons in the 
corpus collosum at P14 (221), little is known about the role of PAK1 in oligodendrocyte 
development. Given its high expression in oligodendrocyte lineage cells (32,171) and its known 
role regulating signaling pathways involved in oligodendrocyte differentiation, we tested the 
hypothesis that PAK1 is required for oligodendrocyte differentiation and myelination. Our 
studies establish that PAK1 increases expression throughout oligodendrocyte differentiation, 
increases during excessive myelin wrapping, and positively regulates myelin production by 
determining F-actin dynamics.  
Methods 
qPCR. All zebrafish were kept at 28.5°, on a 14/10 light cycle at the University of 
Colorado Anschutz Medical Campus, in compliance with NIH and University of Colorado health 
guidelines for animal care. Embryos were raised in Embryo Media (EM) (embryo media recipe). 
Pharmaceuticals used to study PAK1 impact on myelin gene expression were FRAX486 (Tocris 
#5190, cas # 1232030-35-1), NVS PAK1 1 (Torcis # 6132, cas # 1783816-74-9), and G5555 (Tocris 
# 6051, cas # 1648863-90-4). All pharmaceuticals were reconstituted in Dimethyl sulfoxide 
(DMSO). Each pharmaceutical concentration was applied in 1% DMSO in Embryo Media, with a 
sample group of 20 embryos. All conditions were performed in 3 to 5 biological replicates. 
Pharmaceuticals diluted in EM were applied at 2 dpf (days post fertilization), refreshed at 3 dpf, 
and samples were collected at 4 dpf. At collection, embryos were anesthetized with Ethyl 3-
aminobenzoate methanesulfonate salt (tricaine) (Sigma # E10521-10G, cas # 866-86-2), 
 45 
collected into 1.5 mL tubes, liquid was removed, snap frozen in liquid nitrogen and stored at -
80° in Trizol Reagent (Thermo Fisher #15596026). RNA was isolated using Direct-zolTM RNA 
miniprep Kit plus DNase treatment (Zymo Research #R2072). After isolation, 100 ng/ul of mRNA 
was reverse transcribed using iScript™ Reverse Transcription Supermix for RT-qPCR (Biorad 
#1708841). RT-qPCR was performed using Taqman Universal PCR Master Mix (Thermo Fisher 
#4304437) on a StepOnePlus realtime PCR (Applied Biosystems # 4376600). Taqman probes 
were ordered through Thermo Fisher Scientific, mpz (Dr03131915_m1), 36k (flj13639) 
(Dr034338676_m1), and reference genes gapdh (Dr03436842_m1), and rpl13 
(Dr03101114_g1). Mbp (jh71mbp) was designed through Eurofins using the following 
sequences: FWD – 5’-GTTCTTCGGAGGAGACAAGAAGAG-3’, REV- 5’-
GTCTCTGTGGAGAGGAGGATAGATGA-3’. All experiments followed the MIQE Guidelines for qPCR 
(SA Bustin 2009). Data was analyzed using One-Sample T-TEST against the hypothetical control 
value of 1 for statistical significance (p value < 0.05). 
Primary cell culture. All animal experimental protocols were approved by the University 
of Colorado School of Medicine Animal Care and Use Committee (IACUC) and were conducted 
in accordance with the National Institutes of Health guidelines for the care and use of 
laboratory animals. For rat OPCs: mixed glial cultures were generated from P0-P4 Sprague 
Dawley rat pups. The cerebra of rat pups were dissected and homogenized in Hanks Balanced 
Salt Solution following removal of meninges to generate a single suspension. Cells were plated 
into poly-D-lysine (PDL)-coated or poly-L-ornithine-coated flasks and grown in DMEM high 
glucose with 10% fetal bovine serum (FBS), 2mM L-glutamine and 50u/mL PenStrep for 10-12 
days with 3 media changes. Microglia were shaken off for 1 hour at 150rpm at 37°C. Media was 
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replaced and OPCs were purified by shaking overnight at 225rpm at 37°C. The media was 
collected and passed through a 70µm filter. The media was added to uncoated 10-cm dishes 
and incubated for 1 hour at 37°C to remove astrocytes. Media was transferred to 50mL falcon 
tubes and spun for 4 minutes at 1200rpm to pellet OPCs. OPCs were then resuspended in 
media and plated onto acid washed glass coverslips or coated (PDL, Fibronectin, Laminin) 
plastic dishes according to experimental protocol.   
For mouse OPCs, cortices of P0-P2 mouse pups were dissected. 1mL of Papain solutions 
and DNase was added, and gently dissociated by titration. The mixture was incubated at 37C for 
10 minutes, triturated again. 5mL OPC media and 150uL of DNase/brain were added to 
mixtures. Mixture sat at 5 min at room temperature. Tubes were spun at 300xg for 5 min. 
Media was aspirated and pellets were resuspended in 1mL of OPC media. Mixture was added to 
T75 flask with 10mL OPC media, and placed in 8.5% CO2 incubator for 24 hours. Media was 
aspirated off and replaced with 10mL of fresh OPC media. Media was changed on every 2 days. 
On day 8, insulin was added to the media. Microglia were shaken off at 100rpm for 1 hour at 
room temperature. Media was replaced and OPCs were purified by shaking overnight at 
190rom at 37°C. Media was collected and filtered through 40µm filter into non-coated petri 
plates for microglia attachment for 30 minutes-1hour. Media was placed in 15mL falcon tubes 
and psin at 1200rpm for 5 min. Supernatant was removed and cell were resuspended in 
oligodendrocyte media containing PDGF/FGF. Media was changed every 48hours (222).  
shRNA design and implementation. rOPCs were plated on glass coverslips. Plasmid DNA 
containing rat PAK1 shRNA (Target 1: TAAAATTCCAACACATCCA, Target 2: 
TTCCGGGTCAAAGCATCTG, Target 3: ATCCCCGTAAACTCCCCTG, scrambled control: 
 47 
GCTCCACGCTTCACTACCA) was cloned using pSUPER RNAi System (Catalog # VEC-PRT-0002). 
Plasmid DNA was added to Xfect reaction buffer (Xfect Transfection Reagent, Takara Cat. No 
631317). Xfect Polymer was then added to mixture. Mixture was vortexed for 10 seconds and 
incubated at room temperature for 10 minutes. The mixture was spun in a tabletop centrifuge 
and then added dropwise to the cell culture medium. The plates were gently tapped and then 
incubated for 4 hours at 37°C. Media containing the shRNA was removed by aspiration and 
replaced with differentiation media, replaced every 2 days. The cells were incubated at 37°C for 
5 days until analysis. For shRNA in C6 glioma cells, cells were plated on 6cm, plastic dishes. Cells 
were transfected overnight, treated with puromycin for 1 week to select for transfected cells, 
then collected and plated on 6cm dishes (1 mil cells/dish) and collected the next day for 
western blot for PAK1 (Cell signaling 2602) or pLIMK (Cell signaling 3841) protein expression. 
Immunocytochemistry. rOPCs were collected for analysis after 1 hour incubation with 
live stain (1:4 O1/O4 in rOPC media). mOPCS and rOPCs were washed twice with ice cold PBS 
and fixed overnight in 500µl of 4% paraformaldehyde. Cells were rinsed twice with PBS and 
stored at 4°C for immunocytochemistry. Images were taken using Leica DM-6000 confocal with 
a 25X water immersion objective or 63x oil immersion objective. For high magnification, images 
were taken using Nikon N-SIM with 100X TIRF objective. 
Immunohistochemistry. PLP-EGFP mouse (223) was anesthetized with fatal plus, and 
tissue was fixed by transcardial perfusion with PBS followed 4% paraformaldehyde (PFA) at 4°C. 
Brain was dissected, postfixed overnight and transferred to cryoprotection solution (30% 
sucrose in PBS) overnight at 4ºC. Free-floating coronal 30 µm sections were prepared on a 
cryostat (LEICA, CM1950), and sections were stored at 4 ºC in cryostrage solution (30% ethylene 
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glycol, 30% sucrose, and 1% PVP-40 in 0.1M Sorenson’s buffer). Free-floating sections were 
washed in PBS and antigen retrieval was performed with 10mM sodium citrate, pH=6.0, plus 
0.05% Tween20 for 10min at 550W in a PELCO BioWave Pro tissue processor (Ted Pella, 
Redding, CA, USA), followed by washing in PBS. They were then blocked for 1 hr in blocking 
solution (5% normal donkey serum, 0.1% TritonX-100 in PBS). Sections were incubated in 
primary antibodies diluted in blocking solution 2 overnights at 4 ºC. Primary antibodies used: 
rabbit anti-PAK1 (1:500 for P10, 1:50 for 2MO, Cell signaling Technology, Danvers, MA, USA, 
#2602, RRID: AB_330222), goat anti-GFP (1:500, Abcam, Cambridge, MA, USA, ab6673, RRID: 
AB_305643) and rat anti-PLP1 (clone AA3) (Yamamura et al., 1991). After washing with PBS, the 
sections were incubated in biotin-conjugated anti rabbit IgG diluted in blocking buffer overnight 
at 4 ºC. After washing with PBS, the sections were incubated for 2 hr at room temperature with 
Alexa Fluor 488-conjugated Donkey a Goat and Rat IgG (Jackson ImmunoResearch laboratories, 
West Grove, PA, USA), and Alexa Fluor 594-conjugated streptavidin (Jackson ImmunoResearch 
laboratories, West Grove, PA, USA) diluted in blocking buffer. After washing with PBS, the 
sections were mounted on slides and coverslipped in Fluoromount G (SouthernBiotech, 
Birmingham, AL, USA). Images were taken using Leica DM-6000 confocal with a 25X water 
immersion lens. 
Cloning. The tol2kit was to construct plasmids (224). pEXPR-myrf:PAK1 constructs were 
created by subcloning the appropriate PAK1 constructs into the pME plasmid which was then 
used for recombination with p5E-myrf, p3E-2AnlsmCherry, and pDEST-nonet plasmids using the 
Tol2 kit (Table 2.1). The resulting plasmids were verified by restriction digest and verified by 
sequencing.  
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Drug inhibitor experiments.  Pharmacological drugs were dissolved in 100% DMSO 
according to manufacturer instructions. Drugs were diluted in embryo media (EM) to make 
working concentrations with a final concentration of 1% DMSO. Control solutions contained 1% 
DMSO in EM. Zebrafish embryos were collected during timed matings. Transgenic embryos 
were sorted for fluorescence (for internode analysis) or WT embryos (for qPCR analysis) were 
dechorionated and treated with appropriate drug or DMSO control. Drug treatments were 
initiated at 48hpf for all experiments. For internode analysis, fish were treated from 48-72hpf, 
when zebrafish were anesthetized using tricaine (MS-222) and live imaged. For qPCR, embryos 
were treated from 48-96hpf with drug renewal/EM change after 24 hours.  
Inhibitors: FRAX486 (Tocris Bioscience, Cat. No 5190), NVS PAK1 1 (Tocris Bioscience Cat. No 
6132), G 5555 (Tocris Bioscience Cat. No 6051) 
DNA microinjections. For mosaic labeling, zebrafish embryos were collected and 
injected with appropriate DNA constructs at the 1-4 cell stage. Embryos were injected with a 
1nl of a solution containing 15-25ng/µl total plasmid DNA, 20ng/µl tol2 transposase mRNA, and 
10% phenol red. 
Live imaging. All zebrafish experiments completed in this study were approved by the 
Institutional Animal Care and Use Committee at the University of Colorado School of Medicine. 
Embryos were raised at 28.5° in embryo media (EM) and staged according to hours post-
fertilization (hpf), days post-fertilization (dpf), and morphological criteria (Kimmel et al. 1995). 
Zebrafish were anesthetized using tricaine (MS-222). Embryos were mounted laterally in 1% 
low-melt agarose and tricaine and imaged directed above the yolk sac extension on a Leica DM-
6000 confocal with a 25X water immersion lens. Individual myelin internodes were traced and   
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analyzed in 3D using IMARIS image analysis software (Bitplane). Image brightness and contrast 
was increased uniformly in individual images to provide a clear image. 
Results 
PAK1 expression in oligodendrocytes. Pak1 is highly expressed by multiple cell types in 
the brain (225). To investigate Pak1 expression specifically in the oligodendrocyte lineage, we 
studied primary rat oligodendrocyte differentiation to determine Pak1 protein expression 
throughout oligodendrocyte development. PAK1 is expressed throughout the oligodendrocyte 
lineage with highest expression in differentiated oligodendrocytes (Fig. 1A, B). This increase in 
PAK1 protein expression is consistent with PAK1 mRNA levels during OPC differentiation 
(32,171). This suggests that both PAK1 mRNA and protein are expressed throughout the entire 
oligodendrocyte lineage but with increasing expression during OPC differentiation and highest 
expression in myelinating oligodendrocytes (32,171).  By immunocytochemistry, PAK1 localizes 
to both the cell body and the oligodendrocyte processes in differentiated oligodendrocytes in 
vitro (Fig. 1C).  
To assess whether Pak1 is expressed in oligodendrocytes in vivo, we stained our 
transgenic mouse that labels oligodendrocytes with GFP, Plp:EGFP, for Pak1. As with Pak1 
expression in oligodendrocytes in vitro, punctate Pak1 expression was seen in both 
premyelinating and myelinating oligodendrocytes, primarily visualized within the cell body 
(Figure 2.1). This suggests that Pak1 regulates multiple stages of oligodendrocyte development. 
Increasing myelination increases PAK1 expression. Since PAK1 increases expression 
during oligodendrocyte differentiation and is most highly expressed in myelinating 
oligodendrocytes, we tested the hypothesis that increasing myelination would increase PAK1 
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Figure 2.1. PAK1 expression through the oligodendrocyte lineage. (A) PAK1 in vitro in primary 
rat OPCs. PAK1 increases expression during oligodendrocyte differentiation and increases as 
MBP increases expression. (B) Quantification of in vitro expression of PAK1. (C) Representative 
image of PAK1 expression after 5 days in differentiation media. PAK1 is in green, Olig2 is in blue, 
O1/O4 is in magenta. (C, D) PAK1 expression in premyelinating oligodendrocytes (C) or 
myelinating oligodendrocyte (D) in P10 PLP-EGFP expressing mice. EGFP is in green, Pak1 is in 
magenta myelinating oligodendrocytes in P10 PLP-EGFP expressing mice.   
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expression. Our hypermyelinating mouse model driven by constitutively active AKT in 
oligodendrocytes (PLP-AktDD) (54,95) shows increased myelin thickness in the CNS without 
alterations to the number of differentiated oligodendrocytes. These mice continue to actively 
myelinate as adults. Our data demonstrate that in PLP-AktDD mice, which have increased Akt 
expression and increased myelin wrapping in adult mice, also have 4-fold increased  PAK1 
expression (Figure 2.2). To confirm that PAK1 was specifically increased in oligodendrocytes, we 
analyzed WT and PLP-AktDD corpus callosum samples by immunohistochemistry, staining for 
PAK1 plus the transcription factor SOX10 to identify all oligodendrocyte lineage cells and CC1 to 
identify differentiated oligodendrocytes. In PLP-AktDD corpus callosum, there was a clear 
increase in PAK1 expression in differentiated oligodendrocytes (Figure 2.2). This suggests that 
PAK1 is downstream of AKT signaling driving myelination in oligodendrocytes. 
Inhibiting Group I PAKs inhibits PAK activity and decreases myelin gene expression. In 
order to investigate whether and when during development the PAK1 activity was most crucial, 
we analyzed the impact of PAK1 on oligodendrocyte gene expression during development in 
zebrafish. Initial studies used PAK1 pharmacological inhibitors, and before studying them in 
zebrafish, their specificity was established in vitro using the C6 glioma cell line. We stimulated 
PAK1 activity in the cells with IGF and tested three different individual chemical inhibitors. Each 
inhibitor primarily targets PAK1 but also decreases activity of PAK2 and PAK3 (226-228). Since 
Group I PAK activity requires autophosphorylation upon activity, we quantified PAK activation 
by pPAK1Ser141/PAK2Ser141 (229). Inhibiting Group I PAKs with each of the three inhibitors 
decreased PAK1 activity significantly in C6 cells (Figure 2.3). We then used these inhibitors in 












Figure 2.2 Constitutively active AKT increases PAK1 in oligodendrocytes. (A) Representative 
image of WT or AKT-DD cerebellar protein samples. AKT confirms genotype. (B) Quantification 
of PAK1 compared to Tubulin in WT and AKT-DD the cerebellum of adult mice. n = 3 
animals/genotype. **p=0.0064, unpaired t-test (C) PAK1 is increased in oligodendrocytes in 
AKT-DD adult mice in the corpus callosum. PAK1 is labeled in green, CC1 labels differentiated 













Figure 2.3 Pharmacologically inhibiting PAK1 decreases myelin gene expression. (A) C6 cells 
shows a decrease in pPAK1/2 with individual PAK inhibitors after 30 minutes of treatment. (B) 
Quantification of pPAK1/2 expression after addition of PAK inhibitors. n=3 experiments. ** p = 
0.0031, ANOVA with Dunnett’s multiple comparisons test. (C) Groups of 20 zebrafish were 
treated from 2-4dpf with a DMSO vehicle control or one PAK inhibitor, FRAX486, NVS PAK1 1, or 
G5555 in embryo media. Drugs were refreshed daily. * p-value < 0.05, n = 3-5 biological 
replicates per treatment. 
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We tested the three chemical inhibitors for their impact on myelin gene expression in zebrafish 
embryos. Inhibiting Group I PAKs from 2-4 days post fertilization (dpf), during the time of 
oligodendrocyte differentiation and initiation of myelination, led to significantly decreased 
myelin gene expression. FRAX486 was most effective in decreasing myelin gene expression. 
Thus, 3 major zebrafish CNS myelin mRNAs, myelin basic proteins (mbp), myelin protein zero 
(mpz) (230) and 36K (231) were downregulated after treatment with FRAX486, although only 
MBP and 36K downregulation was statistically significant (Figure 2.3). Thus, Group I PAK activity 
is needed for normal myelin gene expression during oligodendrocyte differentiation in 
zebrafish. 
PAK1 regulates actin dynamics and oligodendrocyte differentiation. To determine if 
Group I PAKs regulate OPC morphological differentiation in vivo, we inhibited Group I PAKs 
using the most effective chemical inhibitor (FRAX486). In a transgenic zebrafish line that labels 
the membranes of OPCs, Tg(nkx2.2a:mEGFP), we imaged a lateral view of the spinal cord, and 
found that PAK1-3 inhibition with FRAX486 from 48hpf to 56hpf, just prior to the onset of 
myelination, reduced OPC morphological differentiation. Specifically, the number of OPC 
processes (terminal points) and the total process length per cell were decreased (Figure 2.4). 
Thus, Group I PAKs positively regulate OPC morphological differentiation, which suggests that 
since actin polymerization is required for the initial stages of OPC development, PAK1-3 may 
regulate actin dynamics during this developmental period in OPCs. 
To investigate the mechanism of PAK1 regulation of OPC differentiation and process 
extension, we returned to primary oligodendrocytes and pharmacologically inhibited Group I 
function in vitro in mouse OPCs. As OPCs extend processes, they develop an actin-rich 
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Figure 2.4 Pharmacologically inhibiting PAK1 leads to a decrease in OPC branching 
complexity. (A,B) Tg(nkx2.2a:mEGFP; sox10:tagRFP) embryos were treated with a DMSO 
vehicle control (A) or the PAK1 inhibitor FRAX486 (B) from 48-56hpf, then live imaged. (C,D) 
Images were taken directly above the yolk sac extension. Individual cells were traced and 
analyzed in 3D using IMARIS software. (C) The inhibition of PAK1 lead to a decrease in the total 
length of the OPC branches. *p=0.01, unpaired t-test. (D) The inhibition of PAK1 lead to a 
decrease in the number of OPC terminal points per cell. *p=0.0049 unpaired t-test.  
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lamellipodial-like protrusion at the tip of individual branches that extends back to the cell body 
as the branches expand during initial sheet formation. During sheet expansion, F-actin becomes 
restricted to the outer perimeter of the sheet and is very low in the sheet itself. Inhibiting 
Group I PAKs dramatically reduced the number of actin-rich protrusions in mOPCs, suggesting 
that PAK1 regulates actin dynamics in OPCs (Figure 2.4). 
Inhibiting PAK1 in OPCs decreases OPC branching. To establish that PAK1 activity had a 
major impact on OPC process extension during early stages of OPC development, we utilized 
shRNA to reduce PAK1 expression in oligodendrocytes in rat OPCs (rOPCs) in vitro. Three 
different PAK1 targets and a scrambled control were designed in order to knockdown PAK1 in 
rOPCs. rOPCs have low transfection efficiency, so we confirmed PAK1 knockdown by western 
blot in C6 glioma cells, which have high transfection efficiency. Target 1 showed the most 
significant decrease in PAK1 protein level, and importantly it also decreased the downstream 
PAK1 target, pLIMK, indicating the shRNA targets PAK1 (Figure 2.5). We transfected rOPCs with 
the control or PAK1 shRNA along with a GFP plasmid for 4 hours. We then added fresh 
differentiation media and allowed the cells to grow for 5 days (Figure 2.5). In PAK1 knockdown 
cells (GFP+ cells) OPC branching was decreased, compared to neighboring GFP- cells (Figure 
2.5). This indicates that PAK1 normally promotes OPC process extension and morphological 
complexity. 
PAK1 also regulates myelination. To test the hypothesis that Group I PAKs positively 
regulate later stages of differentiation, i.e., early myelination, we used the same 




Figure 2.5 Inhibiting PAK1 decreases oligodendrocytes morphological complexity. (A) Due to 
low transfection efficiency, PAK1 and the downstream target, pLIMK expression were analyzed 
by western blot using C6 glioma cells shRNA treatment paradigm for transfections. (B) rOPCs 
were grown in rOPC media with PDGF/FGF for 2 days. Cells were transfected for 4 hours, then 
the media was replaced with differentiation media + T3, replaced every 2 days, and collected 
for analysis after 5 days. (C) rOPCs transfected with a scrambled control shRNA (shPAK1-
control) or 3 different PAK1 targets were collected and stained for GFP to show transfection or 
O1/O4 in magenta as a membrane marker. 
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inhibitor during the early stages of myelination, we determined that Group I PAKs positively 
regulated myelin internode length. We treated zebrafish embryos with FRAX486 for 24 hours 
(48-72hpf), imaged a lateral view of the spinal cord, and quantified the myelin produced per 
image. Since PAK1 has also been demonstrated to regulate cell migration (174), we first 
measured the number of dorsally migrated OPCs while inhibiting Group I PAKs. Surprisingly, 
there was no change in the number of dorsally migrated OPCs, quantified by the number of 
dorsally migrated sox10+ cells (Figure 2.6). Interestingly, there was a slight increase in the total 
number of internodes in the spinal cord when Group I PAKs were inhibited (Figure 2.6), but 
importantly, there was a clear reduction in the internode length, an important measure of  
myelin production (Figure 2.6) This suggests that PAK1-3 positively regulates myelination 
without altering cell migration. 
Oligodendrocyte specific PAK1 activity regulates myelin production. The data from 
pharmacological inhibition of Group I PAKs suggests that PAK1-3 positively regulate 
myelination. Since PAK1 is expressed in multiple cell types (Aria-Romero and Chernoff 2008), 
we next altered PAK1 activity specifically in oligodendrocytes. PAK1 dimerizes with another 
PAK1 protein by the autoinhibitory domain (AID) binding to the kinase domain of a second 
PAK1 (Figure 2.7). When a GTPase binds to the GTPase binding domain, this leads to 
conformational changes, autophosphorylation, release of the double inactive PAK1 forms with 
activation of PAK1 (Figure 2.7) (232). Thus, ectopically expressing the AID in a cell expressing 





Figure 2.6. Pharmacologically inhibiting PAK1 leads to a decrease in myelin internode length 
and number. (A,B) Lateral view of zebrafish spinal cord above yolk sack extension. 
Tg(nkx2.2a:mEGFP; sox10:tagRFP) embryos were treated with a DMSO vehicle control (A) or 
the PAK1 inhibitor FRAX486 (B) from 2-3dpf, then live imaged. Square brackets outline 
individual myelin internodes. Arrowheads point to migrated oligodendrocytes. Scale bar is 
50µM. (C) Quantification of dorsally migrated sox10+ cells labeled by Tg(sox10:tagRFP) (D, E) 
Quantification of myelin internode length and number analysis mean per cell. Analysis was 
completed in IMARIS. 
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To determine whether oligodendrocyte PAK1 activity regulates myelin production, we 
used the PAK1 autoinhibitory domain (PAK1 AID) to inhibit PAK1 function in oligodendrocytes 
by cloning the PAK1 AID behind an oligodendrocyte promoter (pEXPR-myrf:PAK1 AID-
2AnlsRFP). The 2A peptide allows for expression of the PAK1 AID separate from the red RFP 
fluorophore. This way, we could determine which cells expressed the PAK1 AID without directly 
tagging the protein. By co-injecting the PAK1 AID along with a plasmid to label myelin 
production, (pEXPR-mbp:mEGFP), we were able to quantify the amount of myelin produced by 
individual oligodendrocytes in WT or PAK1 AID+ cells. This mosaic analysis allowed us to 
quantify multiple aspects of myelin production, including changes in myelin internode length or 
the number of myelin internodes produced by individual oligodendrocytes. Inhibiting PAK1 
specifically in oligodendrocytes decreased myelin internode length without altering the number 
of myelin internodes produced per cell (Figure 2.7). This suggests that PAK1 positively regulates 
myelin production through internode length. As a control, the PAK1 autoinhibitory domain 
containing a mutation that prevents its inhibitory function (pEXPR-myrf:PAK1 AID L107F-
2AnlsRFP) was injected. Injecting this non-functional AID did not alter myelin production (Figure 
2.7). To determine whether the kinase activity is specifically required for myelin production, we 
inhibited PAK1 by expressing a full-length, kinase dead PAK1 (pEXPR-myrf:PAK1 K299R-2A 
nlsRFP). Inhibiting PAK1 kinase activity also decreased myelin internode length without 
changing the number of myelin internodes produced per cell (Figure 2.7). Thus, inhibiting PAK1 
function by expressing the PAK1 AID or a full-length kinase dead mutant decreased myelin 











Figure 2.7 Oligodendrocyte specific PAK1 regulates myelin internode length. (A) Schematic of 
PAK1 protein. PAK1 contains Nck and Grb2 binding domains at the N-terminus. The regulatory 
domain contains a GTPase binding domain (GBD) and an overlapping autoinhibitory domain 
(AID). There is a PIX binding domain and then the kinase domain that contains multiple 
phosphorylation sites, including K299 and T423, both are important for activation of PAK1. (B) 
PAK1 folds into inactive homodimer where the AID of one PAK1 binds to the kinase domain of 
another PAK1, rendering both inactive. When a GTPase binds to the GBD, this leads to 
conformational change, autophosohorylation and activation of the kinase domain. (C) 
Representative images of myelin internodes. Zebrafish embryos were injected with 
pMBP:mEGFP along with a second plasmid to manipulate PAK1 function. Embryos were live 
imaged and internodes were quantified using IMARIS software. Scale bar is 25µM. (D) 
Quantification of internode length. Internode length was determined by the mean length per 
cell. (E) Quantification of internode number. Internode number was determined by the number 
of myelin internodes produced per cell in IMARIS.  
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In a reciprocal experiment, we constitutively activated PAK1 in oligodendrocytes by 
overexpressing a constitutively-active full-length PAK1 mutant. Mutating threonine 423 to 
glutamic acid located in the kinase domain of PAK1 increases the autophosphorylation of PAK1 
and is required for kinase activation (175). After co-injecting pEXPR-PAK1 T423E-2AnlsRFP with 
the myelin marker pEXPR-mbp:mEGFP, myelin internode length and myelin internode number 
produced per oligodendrocyte were quantified. Activating PAK1 specifically in oligodendrocytes 
during myelination significantly increased myelin internode length (Figure 2.7). Together, these 
data show that PAK1 regulates myelination by controlling internode length. 
Discussion 
Our studies demonstrate that PAK1 promotes oligodendrocyte development and myelin 
production through the actin cytoskeleton. PAK1 is expressed throughout the oligodendrocyte 
lineage and most highly expressed in differentiated oligodendrocytes, both in premyelinating 
and myelinating oligodendrocytes. This expression pattern mimics PAK1 RNA expression, which 
also show highest expression in myelinating oligodendrocytes (32,171). Interestingly, despite its 
higher expression in more mature oligodendrocytes, PAK1 is required for OPC morphological 
differentiation during the time of extensive process extension and retraction as well as during 
active myelination (Figure 2.8). Through global inhibition of Group I PAKs, as well as 
oligodendrocyte-specific inhibition of PAK1, we have shown that PAK1 promotes morphological 
differentiation via the actin cytoskeleton, while PAK1 promotes CNS myelination by altering 
myelin internode length and myelin gene expression. 
Oligodendrocyte development has been studied in many contexts, studying both its 
regulation and its impact. Numerous studies focus on how specific signaling pathways and  
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Figure 2.8. PAK1 regulates actin dynamics throughout the oligodendrocyte lineage. (A) PAK1 
regulates actin dynamics in OPC processes. PAK1 may promote myelination by regulating actin 
dynamics at the leading edge during myelin wrapping. (B-E) Model showing actin dynamics 
during oligodendrocyte process extension, axon ensheathment, and wrapping in lateral and 
cross-sectional views. (D) F-actin and G-actin are pictured in the inner tongue for visualization. 
F-actin pushes the inner tongue between previous myelin wraps and the axon. G-actin is in 
multiple myelin wraps. (E) G-actin is pictured in the middle myelin wrap for visualization but is 
present in all layers. G-actin allows for myelin compaction and lateral extension.  
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ultimately the production of myelin are regulated during brain development. Oligodendrocyte 
progenitor cells proliferate and migrate in response to PDGF signaling after which they extend 
numerous processes to differentiate to highly branched premyelinating cells and then 
myelinating cells. Myelin production is driven by mTOR and Erk signaling, which are likely 
interacting pathways during oligodendrocyte development (59,87).The production of these 
highly branched cells and the myelin membrane itself requires extensive cytoskeletal 
rearrangements, and the current studies identify PAK1 as a potential mediator of actin 
structure and function during oligodendrocyte development.  The actin cytoskeleton is 
important during both differentiation and myelination but it plays different roles at these 
different stages of oligodendrocyte maturation (for review see (233)). In OPCs, F-actin localizes 
to OPC branches and is highly expressed at the tips of OPC processes that interact with the local 
environment (62,156). The tips of OPC processes are reminiscent of lamellipodia, spreading out 
like a fan and enriched in the actin cytoskeleton (62,234) (Figure 2.4). Actin polymerization is 
required for OPC process extension where processes extend, contact, and ensheath an axon in 
the early stages of myelin wrapping (61,62). During active myelin wrapping, it is hypothesized 
that filamentous actin localizes to the leading edge of the myelin wrap, expanding and moving 
this inner tongue between the axon and previous myelin wraps. The F-actin is subsequently 
depolymerized immediately behind the inner tongue, allowing for myelin compaction and 
lateral spreading (Figure 2.8) (61,62). Additionally, F-actin maintains cytoplasmic channels 
within myelin in an open state. This allows for movement of myelin proteins and molecular 
machinery throughout myelin, similar to Schmidt-Lanterman incisures in the peripheral nervous 
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system (PNS) (185-187). Thus, F-actin dynamics within myelin require precise, tight control in 
order to control myelin structure and the movement of cytoplasm .  
PAK1 is a small molecule that can be quickly activated and inactivated, providing a 
promising target for regulating these processes. PAK1 activation occurs by more than one 
mechanism, but the canonical activation is by GTPases. Upon GTPase binding, PAK1 dimers 
undergo conformational changes and autophosphorylation, after which the activated PAK1 
phosphorylates LIMK. LIMK then phosphorylates the actin depolymerizing factor cofilin, 
ultimately leading to actin cytoskeletal rearrangement (Fig. 8) (178,232). However, PAK1 can 
also be activated in a GTPase-independent manner, directly through at least 2 signaling 
molecules. PI-3K can directly induce PAK1 activity, after which PAK1 directly phosphorylates 
actin, leading to dissolution of stress fibers (177). AKT can also activate PAK1 in a GTPase-
independent manner, leading to an increase in cell survival (176). Together, these data indicate 
that PAK1 function depends on the upstream activation signal and that both GTPase activities 
and direct PI-3K/Akt signaling may regulate its activity. 
During OPC differentiation, our data suggest that PAK1 drives OPC process extension 
through actin cytoskeletal rearrangements at the edges of OPC processes (Figure 2.4). Both cell 
adhesion molecules and growth factors stimulate PAK1 activation and cytoskeletal regulation. 
For example, neural cell adhesion molecule (NCAM) activates PAK1 in lipid rafts of neuronal 
growth cones (235). Additionally, PDGF is a well-known regulator of early oligodendrocyte 
development (236), and in fibroblasts, it activates and translocates PAK1 to lamellipodia (237). 
Does PDGF activate PAK1 in OPCs? This could lead to PAK1 translocation to the edge of OPC 
processes and actin-rich areas within the OPC to regulate actin dynamics. This is particularly 
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important because OPC processes, and especially the lamellipodia-like process at the edge of 
OPC processes, allow OPCs to interact with the extracellular matrix, other OPCs, and axons 
(62,218,219); such signals from the surrounding environment determine proper OPC spacing, 
and identify which axons to myelinate.   
In addition to an impact on early differentiation, the current studies indicate that PAK1 
controls myelin production by refining myelin internode length (Figure 8). Myelin profiles vary 
along CNS axons. Some axons are continuously myelinated, some have intermittent myelin, 
while others have no myelin at all (66). Additionally, parameters such as myelin thickness, 
myelin internode length or the distance between myelin internodes, nodes of Ranvier, where 
voltage-gated sodium channels are located, are also variable. These unique myelin profiles 
provide a mechanism to adjust neuronal conduction velocity within neural circuits. Alterations 
to myelin internode length have important implications for neuronal function. For example, in 
the auditory system, myelin internode length is a major mechanism regulating conduction 
velocity (64,80), which influences an organisms ability to localize sound. Our studies would 
suggest that PAK1 activity may be one of several regulators of myelin internode length in these 
different contexts. 
 Given its impact on myelin internode length, it is intriguing to speculate that PAK1 could 
localize to the inner tongue during myelin wrapping. Since PAK1 can quickly be activated or 
deactivated, this provides an opportunity to rapidly switch from actin polymerization to actin 
depolymerization that is required to drive myelin wrapping (Figure 8). Alternatively, PAK1 could 
instead modulate signaling pathways, including AKT and ERK1/2, known to promote 
myelination. It is unclear whether PAK1 activation occurs in a GTPase-dependent manner in 
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oligodendrocytes, and it is intriguing to note that PAK1 is increased in Akt-overexpressing 
hypermyelinating mice (Fig.2). It is unknown whether that results from the GTPase-
independent direct activation of PAK1 by AKT that can occur (176) or a consequence of 
continual myelination driven by Akt/mTOR in these mice (54,95) that requires increased PAK1 
activity for increased production of myelin. 
It is apparent that PAK1 activity in myelinating cells must be tightly regulated. PAK1 is 
important in PNS myelination, and its activity impacts myelin in a model of hereditary 
neuropathy with liability of pressure palsies, which has mild myelin dysfunction. These mice 
have a decrease in compound action potential and an increase in F-actin at the paranodes, 
cytoplasmic domains of myelin that contact axons. Importantly, they have increased PAK1 
activity in myelin, suggesting that overactivating PAK1 can also be detrimental for myelination 
(184). Together with our data in the CNS, these data suggest that PAK1 activity must be tightly 
regulated for proper myelination as either too little or too much PAK1 activity is detrimental for 
proper myelination.  
Recent data in the PNS demonstrate that AKT function differs depending on the stage of 
Schwann cell development. Before PNS myelination begins, AKT inhibits Schwann cell 
differentiation through mTOR and its downstream target S6 kinase, but later, AKT promotes 
myelin wrapping through both mTOR dependent and independent pathways (113). Our studies 
indicate that PAK1 impacts two stages of oligodendrocyte development. Could PAK1 function 
through two different mechanisms in oligodendrocytes in the CNS, potentially promoting 
oligodendrocyte differentiation and myelin wrapping via two independent mechanisms?  
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In conclusion, we have shown that PAK1 is a positive regulator of oligodendrocyte 
morphological differentiation and myelination. Exploring the downstream targets of PAK1 in 
myelinating cells will be important for future investigations. It will also be essential to 
determine whether oligodendrocyte PAK1 activity responds to neuronal activity or other 





ROLE OF MTOR IN OLIGODENDROCYTE DIFFERENTIATION AND MYELINATION 
Introduction 
mTOR can regulate multiple aspects of cellular biology, from survival, proliferation, to 
differentiation, indicating that mTOR may function through multiple mechanisms (238). 
Although a significant body of research has determined that mTOR plays important roles in 
oligodendrocyte differentiation and myelination, it is still necessary to determine how mTOR 
promotes oligodendrocyte differentiation and myelination (87,88,95,96,101).  
mTOR regulates multiple downstream processes, including protein synthesis via 
ribosomal protein p70-S6K1 (S6K1) (239,240). S6K1 is a serine/threonine kinase that 
phosphorylates multiple targets involved in protein production such as ribosomal protein S6 
(S6RP), a component of the 40S ribosome (241). S6RP is expressed throughout the 
oligodendrocyte lineage (87) and oligodendrocyte-specific loss of mTOR causes a decrease in 
pS6K1 and pS6RP (58,87,88,101), suggesting that pS6RP is required for oligodendrocyte 
differentiation and myelination. Understanding the regulators of protein synthesis during 
myelination is essential to understanding the mechanism of oligodendrocyte differentiation and 
myelination. While myelin mRNAs, such as plp1, are translated in the ER and PLP protein is 
subsequently transported to the myelin membrane (242,243), local translation also occurs 
within myelin sheaths. mbp mRNA is transported along the cytoskeleton in OPC processes and 
locally translated in myelin sheaths (244-247). The translational differences within 
oligodendrocytes highlight the importance of investigating translational control within the 
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oligodendrocyte lineage. Since loss of mTOR leads to decreased pS6K1 and pS6RP, this suggests 
that S6K1 may act as a positive regulator within oligodendrocyte development. 
mTOR is also known to crosstalk with other pathways, including the ERK1/2 pathway as 
previously discussed. mTOR and ERK1/2 both positively regulate the oligodendrocyte 
development and are able to partially compensate for loss of the other (59,87). Could mTOR 
crosstalk with other pathways? In vitro data suggest that mTOR crosstalks with the BMP 
pathway, but it is unknown if this crosstalk occurs in vivo (88). As BMP is a negative regulator of 
oligodendrocyte differentiation, this suggests that mTOR could function to promote OPC 
differentiation by modulating both positive and negative signals required for differentiation 
(115,137,141).  
In vitro oligodendrocyte development shares clear similarities with in vivo 
oligodendrocyte development but it is necessary to validate in vitro findings in vivo. For 
example, the ERK1/2 pathway promotes OPC differentiation in vitro but loss of ERK1/2 signaling 
does not change the number of differentiated oligodendrocytes in the spinal cord 
(59,60,87,89,121). Instead, ERK1/2 signaling is required for proper myelin maintenance (58-60). 
There are also many signaling pathways, including the AKT/mTOR pathway that is required for 
OPC differentiation both in vitro and in vivo. These findings highlight the requirement to 
validate in vitro findings with in vivo models. Since BMP inhibits oligodendrocyte differentiation, 
this indicates that mTOR may promote differentiation by inhibiting BMP activity.  
Methods 
Cloning. The Tol2kit was used to construct plasmids (Kwan et al. 2007). pEXPR-
myrf:S6K1-KR constructs were generated by subcloning the S6K1 cDNA into the middle entry 
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plasmid. This middle entry plasmid was then used for recombination with p5E-myrf, p3E-
2AnlsmCherry, and pDEST-nonet plasmids, using the Tol2 kit. The resulting plasmids were 
verified by restriction digest and sequencing.  
DNA microinjections. For mosaic labeling, zebrafish embryos were collected and 
injected with appropriate DNA constructs at the 1-4 cell stage. Embryos were injected with 1nl 
of a solution containing 15-25ng/µl total plasmid DNA, 20ng/µl tol2 transposase mRNA, and 
phenol red.   
In vivo pharmacological treatments of larval zebrafish. Pharmacological drugs were 
dissolved in 100% DMSO according to manufacturer instructions. Drugs were diluted in embryo 
media (EM) to make working concentrations with a final concentration of 1% DMSO. Control 
solutions contained 1% DMSO in EM. Zebrafish embryos were collected during timed matings. 
Zebrafish were dechorionated and treated with rapamycin or DMSO control. Drug treatments 
were initiated at 48hpf for all experiments. For internode analysis, fish were treated from 48-
96hpf with a drug refresh at 72hpf. Zebrafish were then anesthetized using tricaine (MS-222) 
and live imaged.  
Live imaging. All zebrafish experiments were approved by the Institutional Animal Care 
and Use Committee at the University of Colorado School of Medicine. Embryos were raised at 
28.5° in EM and staged according to hours post-fertilization (hpf), days post-fertilization (dpf), 
and morphological criteria (248). Zebrafish were anesthetized using tricaine (MS-222). Embryos 
were mounted laterally in 1% low-melt agarose and tricaine and imaged directly above the yolk 
sac extension on a Leica DM-6000 confocal. Individual myelin internodes were traced and 
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analyzed in 3D using IMARIS image analysis software (Bitplane). When needed, image 
brightness and contrast were increased uniformly in individual images. 
Results 
Inhibiting mTOR activity decreases OPC branching complexity. To determine whether 
mTOR regulates OPC morphological differentiation in an in vivo context, I used a membrane-
tethered transgenic zebrafish line Tg(nkx2.2a:mEGFP) that labels OPCs. Using a low dose of 
rapamycin to inhibit mTOR from 48hpf to 56hpf, during OPC morphological differentiation, led 
to a decrease in the number of OPC terminal points per cell, representing the number of 
individual OPC branches (Figure 3.1). Inhibiting mTOR also led to a decrease in overall branching 
complexity, indicated by sholl analysis (Figure 3.1). These data suggest that mTOR regulates 
OPC branching complexity and that mTOR is required for OPC morphological differentiation. 
Inhibiting mTOR increases BMP signaling. To determine whether inhibiting mTOR in 
vivo leads to an increase in BMP signaling, we pharmacologically inhibited mTOR in zebrafish 
embryos from 2-3dpf. To block both mTORC1 and mTORC2, we used the drug Torin 1 
(Henceforth referred to as Torin) rather than rapamycin. Rapamycin binds to FK506-binding 
protein 12 (FKBP12), which then allosterically inhibits mTOR from binding to Raptor in mTORC1 
(110). Originally mTORC2 was thought to be rapamycin insensitive but it was later determined 
that high doses or chronic exposure to rapamycin inhibited mTORC2 in addition to mTORC1 
(110). Since we wanted a more complete mTOR inhibition, we switched to the ATP competitive 
mTOR inhibitor Torin that blocks a majority of mTOR activity. We chose 2-3 dpf because this is 
when the largest increase in myelin gene expression occurs during development   
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Figure 3.1. mTOR inhibition decreases OPC morphological complexity. (A) Individual OPCs 
were analyzed in Tg(nkx2.2⍺:mEGFP) zebrafish embryos treated with a vehicle control or with 
5µM of Rapamycin from 48 hours post fertilization (hpf) to 56hpf. (B) Zebrafish were mounted 
in live imaging media and mounted in low-melt agarose. All images are a lateral view taken 
above the yolk sac extension (black box). (C) or rapamycin treated cell (D) display different 
morphological complexities. Scale bar = 25µM. Individual cells were analyzed using IMARIS 
software to quantify the number of OPC terminal points to quantify the number of OPC 
branches, p < 0.0001, unpaired t-test, error bars are SD (C) or the number of sholl intersections, 
error bars are SEM. Area under curve (arbitrary units) Control 298.2 ±	16.49, Rapamycin 200.8 





Figure 3.2. BMP inhibition rescues decrease in myelin genes after mTOR inhibition in 
zebrafish. A. Zebrafish were exposed to vehicle or mTOR inhibitor from 2-3dpf. Embryos were 
collected for qPCR, n=20 fish per treatment. * p<0.05 compared to vehicle control. Dashed line 
represents vehicle control. B. Zebrafish were exposed to mTOR inhibitor (Torin) or vehicle 
control from 2-3dpf, zebrafish were rinsed twice in embryo media and then treated with vehicle 




(unpublished data from Marnie Preston). Inhibiting mTOR led to a significant decrease in myelin 
gene expression, recapitulating previous data showing loss of mTOR activity impairs OPC 
differentiation and myelination (Figure 3.2). We also found that inhibiting mTOR led to a 
significant increase in BMP signaling with increased expression of the downstream targets ID2 
and ID4. These data indicate that inhibiting mTOR in vivo increases BMP signaling.  
To determine whether inhibiting the BMP pathway could rescue myelin gene expression 
after mTOR inhibition, we first used Torin to inhibit mTOR from 2-3dpf. We then washed out 
the Torin from the embryo media and added LDN 193189 dihydrochloride (henceforth referred 
to as LDN), that inhibits Smad 1/5/8 activation or DMSO as a control. We found that inhibiting 
BMP after mTOR inhibition rescued myelin gene expression in a dose dependent manner. 
Specifically, adding higher concentrations of LDN led to a greater increase in mpz gene 
expression compared to the DMSO control (Figure 3.2). 
Inhibiting S6K1 decreases internode number. One of the major downstream targets of 
mTOR is S6K1. While many groups have demonstrated loss of mTOR decreases S6K1 
phosphorylation, it is unclear whether directly altering S6K1 activity would inhibit myelination. 
Thus, to determine if S6K1 activity regulates myelin production in an in vivo system, a kinase-
dead version of S6K1 driven by an oligodendrocyte-specific promotor was injected to inhibit 
S6K1 function in zebrafish oligodendrocytes. This plasmid also contained a 2A peptide cleavable 
NLS-mCherry, which labels the nuclei of cells expressing the S6K1-KR with mCherry without 







Figure 3.3. Inhibiting S6K1 kinase activity in oligodendrocytes decreases myelin production in 
vivo. Representative images of myelin internodes. Zebrafish embryos were injected with 
pMBP:mEGFP along with a second plasmid to manipulate S6K1 function, labeled with mCherry 
or treated with the mTOR inhibitor rapamycin from 2-4dpf. All images are taken in the ventral 
spinal cord above the yolk sac extension. (A) WT cell expressing pMBP:mEGFP to label 
internodes. (B)  A cell expressing both pMBP:mEGFP to label internodes and pMYRF:S6K1-KR to 
inhibit S6K1 function, labeled with mCherry (arrowhead). (C) pMBP:mEGFP+ cell in rapamycin-
treated zebrafish. (D) Quantification of myelin internode length averaged per cell. (E) 
Quantification of myelin internode number averaged per cell. (F) Sum of myelin produced per 
cell. All images were analyzed in 3D using IMARIS software. *p=0.0265, **p = 0.0061, 




pMyrf:S6K1-KR). By co-injecting the S6K1 mutant with a plasmid to label myelin production 
(pEXPR-MBP:mEGFP, henceforth referred to as pMBP:mEGFP), we were able to quantify the 
amount of myelin produced by individual oligodendrocytes in WT or S6K1-KR+ cells. This mosaic 
expression allowed us to quantify several aspects of myelination, including the number of 
myelin internodes produced per cell and the length of individual internodes for an individual 
cell. Cells expressing the kinase-dead S6K1 plasmid had fewer myelin internodes per cell, but 
there was no change in the myelin internode length. Thus, inhibiting S6K1 in a cell-specific 
manner decreased total myelin production per cell primarily by reducing the number of total 
internodes. These results demonstrate that S6K1 positively regulates myelin production (Figure 
3.3). 
To determine if inhibiting mTOR in vivo led to a similar phenotype as S6K1 inhibition, we 
injected embryos at the one-cell stage with a plasmid to label myelin internodes, pMBP:mEGFP, 
and treated zebrafish with the mTOR inhibitor rapamycin or DMSO vehicle control from 2-4 
days post fertilization (dpf). We found that inhibiting mTOR led to a decrease in myelin 
internodes produced per cell without altering myelin internode length. These results 
demonstrate globally inhibiting mTOR in vivo leads to a decrease in myelin production, similar 
to oligodendrocyte-specific S6K1 inhibition. These data suggest that mTOR and S6K1positively 
regulate myelin production. 
Discussion  
The data presented here demonstrate that the mTOR pathway positively regulates 
oligodendrocyte development through multiple mechanisms. Specifically, the data indicate that 
mTOR promotes oligodendrocyte morphological differentiation, myelin gene expression, and 
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myelin production by inhibiting BMP signaling. The data also show that one of the downstream 
targets of mTOR, S6RP, modulates myelin protein production. Together, these investigations 
support previous findings that mTOR is required for oligodendrocyte differentiation and 
myelination (96,201). 
Previous studies in rodents that pharmacologically or genetically inhibited mTOR found 
that mTOR promoted differentiation using markers such as adenomatous polyposis coli clone 
CC1 (CC1) that label the cell bodies of mature oligodendrocytes (96,201). These studies 
provided valuable insight into oligodendrocyte development. However, OPCs are extremely 
motile cells that extend myriad processes into the local environment and this morphology is 
challenging to visualize with cytoplasmic protein markers. Thus, using a membrane-tethered 
EGFP marker provided a tool to visualize both the oligodendrocyte cell body, as well as the 
multiple process extensions under normal conditions or after loss of mTOR function. The data 
presented here indicate that mTOR promotes OPC branching complexity. Since 
oligodendrocytes increase morphological complexity as they differentiate, this is consistent 
with the hypothesis that mTOR promotes oligodendrocyte differentiation. It will be particularly 
interesting to determine the upstream signaling modulating mTOR function during this time of 
process extension and retraction. Are local signals from the extracellular environment signaling 
through receptors within processes or is mTOR promoting OPC morphological complexity 
through signaling pathways instigated in the soma? 
Investigating the local signals that regulate oligodendrocyte differentiation is an area 
that requires further investigation. Signals have been identified that may regulate this process 
but the results are inconclusive as to whether or not they are required for proper 
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oligodendrocyte differentiation and myelination. For example, axonal expression of neuregulin 
(Nrg1) leads to activation of ErbB receptors in Schwann cells in the PNS or oligodendrocytes in 
the CNS. While Nrg1 promotes Schwann cell differentiation and myelination (249), the role of 
Nrg1 in the CNS is inconclusive. In vitro data suggests that Nrg1 is required for early 
oligodendrocyte development, including specification and differentiation (250-252). Loss of 
Nrg1 in the CNS does not affect myelination but overexpression of Nrg1 leads to 
hypermyelination (253). These conflicting data highlight that signaling between the local 
environment and OPCs require further investigation, especially with the recent studies that 
highlight the dynamic and interactive nature of OPCs during differentiation.  
Once OPCs differentiate, they can begin to produce myelin. The data presented here 
indicate that one of the downstream targets of mTOR, S6K1, promotes myelin production by 
regulating the number of myelin internodes produced per cell. This is similar to myelin 
production after pharmacological inhibition of mTOR with rapamycin (Figure 3.3), and given 
that S6K1 is a major downstream target of mTOR, this suggests that these proteins may act 
through the same pathway. It would also be interesting to determine if inhibiting S6K1 
decreased translation of specific mRNAs or led to a global decrease in myelin proteins. While 
published data as well as the data presented here agree that mTOR promotes myelination, the 
myelin parameters leading to the decrease in myelin production after mTOR inhibition vary. 
Previous studies in zebrafish found that treatment with rapamycin alters myelin production by 
decreasing both the number of internodes produced per cell and myelin internode length 
(97,254). These studies investigated the dorsal spinal cord, different from the ventral spinal 
cord population reported here. Additionally, groups used different transgenic markers to label 
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myelin internodes, and variations in the duration of pharmacological treatment that may also 
account for differences in findings.  
The in vivo data demonstrating that mTOR inhibition leads to an increase in BMP 
signaling corroborates similar in vitro findings. Changes in the transcription of ID2 and ID4 
suggest global changes to the BMP pathway. Importantly, inhibiting BMP after mTOR inhibition 
can rescue myelin gene expression. However, these data do not indicate how mTOR inhibits 
BMP signaling. There are multiple steps required for BMP signaling. First, BMP is secreted and 
binds to a complex of receptors, leading to intracellular phosphorylation of SMADs. This is 
followed by cofactor binding and subsequent translocation into the nucleus. Numerous 
cofactors interact with this complex, leading to transcription of downstream targets such as ID2 
and ID4. Thus, there are multiple levels where mTOR could crosstalk with the BMP pathway. 




DISCUSSION AND CONCLUSIONS 
 The data presented here add significant insight into the molecular regulation of 
oligodendrocyte differentiation and myelination. These studies focus on downstream signaling 
targets in the AKT pathway and are broken into two main sections. One section focuses on the 
role of mTOR during oligodendrocyte differentiation and myelination. These experiments were 
completed in a highly collaborative process with colleagues at Rutgers University with the goal 
of broadly understanding how major signaling pathways regulate the process of 
oligodendrocyte development and myelination. The evidence presented here add insight to the 
mechanism of how mTOR functions within the oligodendrocyte lineage through downstream 
targets such as S6K1, as well as interactions with the BMP signaling pathway. These studies add 
to the existing body of literature establishing the essential role of mTOR in CNS glial cell 
development. 
In addition to the highly collaborative project investigating the broad role of mTOR 
throughout oligodendrocyte development, I also focused on a mechanistic investigation of 
myelination. Thus, this section focuses on the role of the cytoskeletal regulator PAK1 
throughout the oligodendrocyte lineage. These data explore a novel mechanism where PAK1 
could drive movement of membrane through the cycling of the actin cytoskeleton. The data 
indicate that PAK1 promotes oligodendrocyte morphological differentiation by modulating the 
actin cytoskeleton and specifically regulates myelin internode length. The evidence shows that 
increasing AKT activity in oligodendrocytes, which leads to hypermyelination, also increases 
oligodendrocyte-specific PAK1 expression. Both sections of this thesis highlight the important 
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role of the AKT pathway throughout oligodendrocyte development. They also show that AKT 
functions through multiple pathways to promote oligodendrocyte differentiation and 
myelination.  
The role of mTOR during oligodendrocyte differentiation and myelination 
 Myriad studies show that mTOR is a positive regulator of oligodendrocyte 
differentiation and myelination. However, there is limited insight into the mechanism by which 
mTOR modulates oligodendrocyte development. The studies presented here add significant 
insight into how mTOR functions in the oligodendrocyte lineage.  
 mTOR promotes OPC process extension. The studies presented here show that 
inhibiting mTOR leads to a decrease in OPC process extension (Figure 3.1). OPC process 
extension Is particularly important for OPCs to interact with the local environment, including 
neighboring OPCs, as well as determining which axons to myelinate. With fewer processes, this 
may suggest that OPCs are unable to determine proper spacing with neighboring OPCs or that 
OPCs may not be able to determine which axons to myelinate. It is interesting to note that in 
the ventral spinal cord, inhibiting mTOR did not alter the number of myelin internodes 
produced per cell but rather decreased the length of individual myelin internodes. Taken 
together, these data may indicate that a higher percentage of OPC processes may produce 
myelin internodes. When an OPC contacts a neighboring OPC, it will retract processes and 
migrate to another location (218,219). It would also be interesting to determine whether OPC-
OPC interactions are reduced or whether OPC spacing is altered after mTOR inhibition. 
mTOR inhibits BMP during oligodendrocyte differentiation. The data presented here 
indicate that loss of mTOR causes a decrease in myelin gene expression and simultaneously 
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increases BMP signaling in vivo. This validates in vitro data that show inhibiting mTOR in 
primary cells increases ID2 and ID4 expression (88). Future work will need to determine exactly 
how mTOR regulates BMP signaling. Alternatively, BMP could inhibit differentiation by 
inhibiting mTOR. However, inhibiting pathways sequentially indicates that mTOR regulates BMP 
rather than BMP inhibiting mTOR. Particularly, pharmacologically inhibiting mTOR from 2-3dpf 
and then inhibiting BMP from 3-4dpf can rescue myelin gene expression, suggesting that mTOR 
inhibits BMP signaling rather than BMP inhibiting mTOR function. However, more experiments 
will need to be completed. Does increasing mTOR activity lead to a significant decrease in BMP 
signaling? Does inhibiting BMP signaling increase mTOR activation? There are multiple 
possibilities for how mTOR could inhibit BMP activity. Since mTOR regulates protein translation, 
it is possible that mTOR could decrease translation of proteins required for BMP signaling, thus 
leading to decreased expression of the ID family members.  
The role of S6K1 during myelination. Myriad studies indicate a functional role of S6K1 in 
oligodendrocyte differentiation and myelination (59,87,255). Loss of mTOR or ERK1/2 leads to a 
loss of pS6K1 (59,239). The data presented here demonstrate that S6K1 promotes myelin 
formation by determining the number of myelin internodes produced per cell (Figure 3.3). S6K1 
is a kinase that targets S6RP, part of the 40S ribosomal subunit. Surprisingly, loss of S6RP or 
S6K1 does not decrease overall protein synthesis but does lead to a decrease in cell size 
(256,257). Instead, loss of S6K1 leads to altered transcription of the ribosome biogenesis 
program (256). These data indicate that S6K1 plays important roles in cellular physiology and 
does not necessarily influence protein synthesis but functions through other, undetermined 
mechanisms. Since one of the main functions of mTOR is to regulate protein translation. This 
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has widely been assumed to function through inhibition of the downstream targets S6K1 and 
S6RP. However, since loss of S6K1 or S6RP does not appear to affect translation, this could 
indicate that mTOR regulates translation primarily through other targets such as 4-EBP1-3. 
mTOR phosphorylates and thus inhibits 4-EBP1-3 activity. This allows the release of the 
eukaryotic initiation factor eIF4E and promotes translation.   
 Investigating the role of S6K1 is important to understand oligodendrocyte myelination 
within the CNS since one of the main targets of S6K1 is S6RP and loss of either mTOR or ERK1/2 
inhibits S6RP activation (59,87,113). Global loss of S6K1 leads to a decrease in body size and 
upregulation S6K2 mRNA (132,258,259). Since S6K2 that shares 80% homology with S6K1, this 
suggests that S6K2 upregulation may compensate for loss of S6K1. This may also indicate that 
inhibiting both S6K1 and S6K2 would lead to a greater decrease in myelin production than 
inhibiting S6K1 alone.  
The S6Ks may also be another area for crosstalk or compensation between the 
AKT/mTOR and ERK1/2 signaling pathways. ERK1/2 has been shown to phosphorylate S6K2 
(260). Additionally, S6RP is a target of both the AKT/mTOR and ERK1/2 signaling pathways 
(87,99,116,241). Loss of S6K1 kinase activity may also lead to an upregulation in the ERK1/2 
target p90RSK, which also phosphorylates S6RP, as a compensatory mechanism to ensure 
phosphorylation and activation of S6RP. Since loss of S6K1 decreases S6RP but does not 
decrease protein synthesis, it will be interesting to determine whether other targets of S6K1, 
such as rictor (part of mTORC2), show decreased phosphorylation that may account for the 
decrease in myelin production. Alternatively, changing pS6RP may alter protein interactions 
that may be important for myelin production. 
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The role of PAK1 during oligodendrocyte differentiation 
 Both in vivo and in vitro manipulations show that PAK1 is a positive regulator during the 
early stages of oligodendrocyte differentiation. The data presented here demonstrate that 
PAK1 promotes oligodendrocyte morphological differentiation via actin at the tips of OPC 
processes. OPC process extension is extremely important for early oligodendrocyte 
development. OPCs are incredibly dynamic cells that survey the surrounding environment to 
ensure the proper OPC spacing and homeostasis within the CNS (218,219). As OPCs 
differentiate, they increase the number of branches and the number of filopodial-like processes 
extending off of each branch. OPCs interact with neighboring OPCs within the local 
environment, providing information to maintain a constant OPC population. OPCs also migrate 
in non-linear paths, suggesting OPCs integrate local, extracellular cues to guide them to their 
final destination. When one OPCs dies, another cell will migrate and enter the emptied 
territory. Additionally, when one OPC interacts with another, the first will retract processes and 
migrate away from the neighboring cell, suggesting OPCs ensure proper spacing through self-
repulsion (218,219). The signals that regulate these dynamics are unknown.  
One potential molecule that could regulate OPC spacing is down syndrome cell adhesion 
molecule (DSCAM). DSCAM is a receptor protein that regulates cellular dynamics in the CNS 
(261). Originally identified in flies for its homophilic binding to other DSCAM molecules, DSCAM 
provides a signal for self-avoidance within individual neurons or mosaic spacing between 
neurons of specific subtypes. However, DSCAM can also provide attractive axons guidance cues 
by acting as a Netrin receptor, demonstrating that DSCAM function is cell type specific (262). 
DSCAM additionally regulates neuronal complexity by localizing PAK1 to the membrane, 
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stabilizing F-actin and promoting dendrite formation (263,264). Since DSCAM is expressed in 
OPCs but only very lowly expressed in myelinating oligodendrocytes (171), it would be 
interesting to determine whether DSCAM regulates PAK1 localization and activation as OPCs 
increase morphological complexity throughout differentiation.  
 Additionally, it would be useful to determine whether PAK1 is activated 
(phosphorylated) and localized to the edges of OPC processes during OPC process extension 
and whether this activation and localization changes during OPC process retraction. Since PAK1 
can be quickly activated/deactivated by phosphorylation, PAK1 could act as a molecular switch 
to change from actin polymerization to actin depolymerization during the dynamic 
morphological differentiation of OPCs.  
The role of PAK1 during CNS myelination 
PAK1 promotes myelin formation by determining myelin internode length. It remains 
unclear exactly how this is accomplished and multiple mechanisms are possible. One possibility 
is through PAK1 regulation of actin at the leading edge during myelin wrapping. PAK1 can 
regulate the actin cytoskeleton by phosphorylating LIMK, which then phosphorylates, and 
inactivates, the actin-severing protein cofilin. Thus, phosphorylation could provide a rapid 
signaling mechanism to cycle between actin polymerization and actin depolymerization. This is 
an intriguing possibility but multiple questions remain. First of all, is PAK1 located at the inner 
tongue to promote this polymerization/depolymerization cycle? The in vitro staining showed 
PAK1 in both the cell body as well as oligodendrocyte processes. This suggests that PAK1 could 
be acting at multiple locations, including the edge of the oligodendrocyte process that will 
become the leading edge during myelin wrapping. The in vivo staining shows PAK1 clearly in the 
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cytoplasm of the cell body. Due to diffuse staining, it is not possible to tell whether PAK1 is 
within the myelin sheath or not. Pursuing immune-gold EM for PAK1 could provide important 
insight into the localization of PAK1 within the myelin sheath. It would also be useful to 
determine if phosphorylated PAK1 is active at the inner tongue. Using a photoactivatable PAK1 
to stimulate PAK1 activity throughout the oligodendrocyte lineage and at specific locations 
within the cell or myelin sheath to determine PAK1 functions would be particularly useful. This 
could also provide insight as to whether PAK1 regulates different signaling pathways in the cell 
body compared to within myelin itself.  
Another important aspect to discuss is the role of cofilin during myelination. One 
hypothesis presented by Zuchero and colleagues suggests that under normal conditions, actin 
severing proteins, including cofilin and gelsolin, are bound to PIP2 at the membrane. However, 
during myelination, MBP outcompetes cofilin and gelsolin for PIP2 binding, leading to release of 
cofilin and gelsolin into the cytoplasm where they can sever F-actin (61). This is an intriguing 
hypothesis. However, the ratio of cofilin to actin is particularly important to understand cofilin 
function and has not been addressed during myelination. At low concentrations of cofilin, 
cofilin will bind to F-actin, induce a twist in the filament and sever the filament. However, at 
higher concentrations of cofilin, many cofilin molecules can bind to F-actin and induce a twist 
throughout the filament, thus stabilizing the filament rather than severing it (167). It will be 
important to identify whether these cofilin and the upstream regulators, such as PAK1, actually 
localize to the inner tongue during myelin wrapping.  
Since PAK1 is most highly expressed in myelinating cells and increases during 
hypermyelination, it will also be necessary to determine the mechanism of PAK1 activation in 
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oligodendrocytes. Our in vivo data indicate that expression of either the PAK1 autoinhibitory 
domain (AID) or a full length kinase dead PAK1 decreases myelination. This suggests that PAK1 
kinase activity promotes myelination but does not rule out the possibility that the regulatory 
domain also influences myelination. Although not significantly different, the PAK1 AID induced 
a greater decrease in internode length than did the full length PAK1 kinase dead mutant (Figure 
2.7). This would suggest that both the regulatory domain and the kinase domain function to 
increase myelin internode length. In vitro work demonstrated that the regulatory domain is 
required for full AKT activation in fibroblasts. Specifically, PAK1 binds to AKT and then 
translocates AKT to the membrane where it undergoes phosphorylation and activation (181). 
This presents multiple mechanisms for PAK1 activity. Could the regulatory domain be required 
for AKT translocation and activation in oligodendrocytes and then the kinase domain regulate 
the actin cytoskeleton? It may also be possible that PAK1 promotes myelin production 
independently of the actin cytoskeleton.  
Our in vitro data show PAK1 expressed in both the cell body and oligodendrocyte 
processes. How does PAK1 localization within an oligodendrocyte change? In human breast 
cancer cells, hepatocyte growth factor (HGF) causes PAK1 to translocate from the cytoplasm to 
the edge of lamellipodia (265). Thus, it is possible that growth factors stimulate PAK1 
translocation to the inner tongue during myelin wrapping. This could be accomplished through 
PAK1 translocating through cytoplasmic channels within the myelin sheath. Since cytoplasmic 
channels are open during active myelination and close during myelin maintenance, this 
provides a mechanism for signaling molecules to move from the cell body to the inner tongue 
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(185,187). This could provide a mechanism for PAK1 to move throughout myelin to the inner 
tongue during active myelination.  
Loss of PTEN increases the number of open cytoplasmic channels, increased myelin 
wrapping and increased AKT activity (187,266). It would be interesting to determine whether 
loss of PTEN also leads to increased PAK1 expression and whether PAK1 localizes to the open 
cytoplasmic channels within the myelin. The central hypothesis proposed here suggests that 
PAK1 promotes myelin wrapping by regulating actin polymerization and depolymerization at 
the inner tongue. However, it is possible that PAK1 plays a different role during myelin 
wrapping. One possibility is that PAK1 could regulate actin dynamics near cytoplasmic channels. 
F-actin blocks membrane compaction and increases cytoplasmic channels within myelin sheaths 
(185,267). Cytoplasmic channels provide access to the inner tongue and the axon-glia interface. 
Importantly, this allows transportation of myelin proteins such as Plp1 or molecular machinery 
within compact myelin (268). Thus, cytoplasmic channels allow for myelin production. There 
are also alternative possibilities to PAK1 translocation from the oligodendrocyte cell body to 
myelin. PAK1 mRNA could be transported to specific areas within myelin and locally translated. 
It would be necessary to determine PAK1 mRNA localization within oligodendrocytes and 
myelin to determine if this is a viable possibility. 
Previous data shows that PAK1 is activated by cell adhesion molecules in neuronal 
growth cones. Specifically, neural cell adhesion molecules directly bind PAK1 in lipid rafts, 
cholesterol and glycosphingolipid-enriched microdomains in the plasma membrane (235,269). 
Interactions with cell adhesion molecules indicate that PAK1 integrates signals from the 
extracellular environment to the rest of the cell. Integrating extracellular signals is especially 
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important for oligodendrocyte development. Since PAK1 is expressed in OPC processes and 
inhibition of PAK1 leads to a dramatic reduction in the fans at the edge of OPC processes, this 
may indicate that PAK1 integrates extracellular signals to the cell body. Axonal cell adhesion 
molecules could also stimulate PAK1 activity. This is of particular importance as OPCs extend an 
actin-rich fan during initial contact with an axon (62).  
One of the oligodendrocyte proteins expressed at the axon-glial interface is the 
transmembrane protein myelin associated glycoprotein (MAG). MAG makes up a small portion 
of myelin but its localization is quite intriguing. The extracellular domain binds to ligands on the 
axonal surface membrane. Interestingly, MAG and NCAM are in the same immunoglobulin 
super family (217). Since MAG is expressed at the axon-glia interface and shares structural 
similarities with cell adhesion molecules known to stimulate PAK1, MAG may be an 
oligodendrocyte-specific stimulator of PAK1 at the leading edge. While MAG null mice show 
relatively normal compact myelin, there is redundant myelin in the CNS and supernumerary 
myelin sheaths (270). In oligodendrocyte cell culture, cross-linking MAG with an anti-MAG 
antibody (simulating axon ligand binding) led to decreased F-actin levels within the membrane 
without altering tubulin or general oligodendrocyte morphology (271). Additionally, in the PNS 
MAG co-localizes with F-actin at periaxonal membranes, as well as Schmidt-Lanterman 
incisures, suggesting MAG may interact directly or indirectly with the actin cytoskeleton (272). 
Cytoplasmic channels have only recently been identified using high pressure freezing methods 
that preserve myelin and it is unknown whether MAG associates with cytoplasmic channels in 
the CNS (187). Together, these data indicate that MAG may regulate F-actin in 
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oligodendrocytes. PAK1 may mediate this regulation through LIMK and cofilin, known 
downstream targets. 
Another remaining question is what directly activates PAK1? Although PAK1 is 
upregulated in oligodendrocytes with increased AKT activity, it is unclear whether AKT directly 
activates PAK1 or whether AKT increases translation of PAK1 protein. GTPases can bind to the 
GTPase binding domain, leading to conformational changes and autophosphorylation events to 
activate PAK1 while AKT can also activate PAK1 in a GTPase independent manner (176). Future 
investigations will need to clarify the mechanism of activation. PAK1 has also been shown to 
activate AKT both through kinase dependent and kinase independent mechanisms, indicating 
that PAK1 could be both upstream or downstream of AKT (181,273). Rather than AKT activating 
PAK1, AKT activation could increase translation of PAK1, and PAK1 levels could increase to 
translocate AKT to the membrane, acting in a positive feedback loop. Further investigations will 
need to clarify where PAK1 functions within the AKT pathway. 
Increasing AKT activity in oligodendrocytes leads to hypermyelination and increased 
PAK1 levels. It would be interesting to examine whether inhibiting PAK1 could reduce myelin 
levels in this model. It would also be intriguing to determine whether other models of 
hypermyelination also show increased PAK1 levels. If PAK1 was continually activated in 
oligodendrocytes, would this also lead to increased myelin thickness? With our zebrafish 
model, we were able to show that inhibiting PAK1 led to a decrease in myelin internode length 
while constitutively activating PAK1 increased myelin internode length. Since constitutively 
activating AKT in oligodendrocytes increases myelin thickness and also leads to increased PAK1 
expression, this adds to the body of literature demonstrating that myelin thickness and length 
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are correlated. However, it is still unclear whether this is a linear relationship. There may be 
other parameters that determine myelin internode length. 
Multiple studies suggest a linear relationship between axon diameter and myelin 
internode length (274-276). Although there is a significant correlation between axon diameter 
and internode length, with smaller diameter axons surrounded by shorter myelin internodes, 
there is variation in myelin internode lengths within axons of the same diameter. This variability 
and weak correlation between axon diameter and internode length suggests that other signals 
beside axon diameter may regulate myelin internode length.  
Current data supports a combination of regulatory elements that regulate internode 
length. Data suggest that internode length is influenced both by intrinsic oligodendrocyte-
specific signaling as well as neuronal signals (77,277). Specifically, Bechler and colleagues 
determined that oligodendrocytes from the spinal cord produce longer internodes than 
oligodendrocytes from the cortex. This difference disappears when oligodendrocytes are 
cultured with neurons or in cerebellar slice culture, indicating that neuronal activity may 
regulate myelin internode length. Monocular deprivation also leads to a decrease in myelin 
internode length without changing myelin thickness and alters conduction velocity, suggesting 
that neuronal activity regulates myelin properties. Bellesi 2018 also demonstrate that chronic 
sleep deprivation leads to decreases in myelin thickness without altering internode lengths 
(278). Together, these data suggest that there are both innate and extrinsic properties that 
regulate myelin properties such as internode length and that internode length may be 
independent of myelin thickness. Since PAK1 regulates myelin internode length, it will be 
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important to determine whether PAK1 responds to extrinsic signals, such as neuronal activity, 
or whether PAK1 activity is a cell intrinsic response. 
Overall Implications 
 In conclusion, these studies add significant insight into the signaling pathways and 
molecular regulation of oligodendrocyte morphological differentiation and myelin production. 
On a more basic level, the data presented here add to a growing body of literature that indicate 
the AKT/mTOR pathway regulates membrane process extension through multiple mechanisms. 
We provide evidence using an in vivo model that during oligodendrocyte development, mTOR 
promotes OPC process extension during morphological differentiation. During this 
differentiation process, mTOR also promotes myelin gene expression by suppressing BMP 
signaling while the downstream target S6K1 promotes myelin membrane production by 
determining the number of myelin internodes produced on an individual cell basis. Additionally, 
increasing AKT activity in oligodendrocytes increases PAK1 expression. We also provide 
evidence that PAK1 promotes OPC process extension, as well as the lateral expansion of myelin 
internodes during developmental myelination. With multiple similarities between 
developmental myelination and remyelination, these studies suggest the Akt/mTOR pathway, 
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